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1. Introduction 
 
1.1  General 
 
People have always dreamt of being able to create human parts in order 
to replace their own diseased or malfunctioning organs or even to 
enhance their own abilities. Wooden and metallic prostheses were the 
only option for the better part of history. In 1818, Dr. Frankenstein (Mary 
Shelley 1818) managed to reanimate a person made of body parts of 
dead people, giving it life through an electrical discharge. This abstract 
element of life that was imagined by fiction authors and could reanimate 
dead human parts was a key element in science for several centuries and 
differentiated living from dead materials, termed organic and inorganic, 
according to their ability to be melted (inorganic) or cooked (organic) 
when heated. It was not until the early 17
th
 century when the discovery 
of microscope managed to shed some light by leading to the discovery of 
the first microorganisms and giving rise to the germ theory of disease, i.e. 
the notion that microorganisms are the cause for various medical 
disorders. It was 200 years later, though, that the final blow was given by 
Friedrich Wöhler, the German chemist who managed to synthesise 
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organic from inorganic materials (urea from ammonium cyanate) in the 
laboratory [Wöhler 1828].  
183 years later, the definition of organic and inorganic molecules has 
been changed completely, modern medicine can transplant human 
organs, it can make three dimensional pictures of a complete body, it can 
even reanimate patients using electrical discharges; modern science has 
matched and in many cases surpassed 19
th
 century science fiction, yet 
scientists have not been more successful than Friedrich Wöhler in their 
quest for creating life from zero. Instead they have become proficient in 
working with the smallest elements of life available – cells – and opened 
the way for new methods of improving and repairing tissue and organ 
functions. This led to the creation of a new scientific discipline, about 20 
years ago. According to Dr. Charles Vacanti [Vacanti 2006] the term 
“Tissue Engineering” was first used in its present context in an article 
published in 1991. 
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1.2 Tissue Engineering 
 
Tissue Engineering can be broadly defined as the generation of new 
tissue using the principles of engineering and an understanding and 
application of biological sciences [Vacanti 2006]. Somewhat more specific 
is the definition stating that “Tissue Engineering is an interdisciplinary 
field that applies the principles of engineering and the life sciences 
towards the development of biological substitutes that restore, maintain, 
or improve tissue function” [Langer & Vacanti 1993]. Tissue Engineering 
(TE) evolved as an alternative treatment method in cases of organ failure. 
The only reliable method for long term treatment today is organ 
transplantation, which suffers severely from lack of donors. In March 
2011 there were more than 110.000 people in the United States waiting 
list only [UNOS 2011]. People wait for years, supported by machines such 
as haemodialysis patients and many die before they have the change to 
receive a transplant (20% of all adults in waiting lists for kidney 
transplants died every year, between 1991 and 1997 [Zhang et al. 2004]). 
Organ rejection is also quite common and it can reach percentages up to 
90% as in the case of lung transplantation [Orens & Garrity 2009]. 
Surgical procedures offer solutions in some cases, such as the 
cardiovascular disease, but they can lead to further complications and 
death. A meta-analysis on people who underwent bypass surgery 
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between 1990 and 2003 showed a 2,1% 30-day mortality rate [Nalysnyk 
et al. 2003]. 
TE, after its introduction as an alternative, revolutionary treatment that 
would create complete functioning organs within 10 years, by the end of 
the 90s enjoyed a big amount of publicity. Eventually, and while it did not 
deliver the expected miracles within a short time, the media turned their 
attention elsewhere and TE continued its course, advancing at a normal 
pace. That said, it does not mean that its achievements have not been 
impressive. An extensive variety of tissue types have been developed in 
vitro including skin, bone, cartilage, ligament, cardiac, vascular and 
valvular tissue [Bilodeau & Mantovani 2006; Priya et al. 2008]. 
 A tissue engineered construct requires three basic elements: cells, 
scaffold and stimuli. The cells are the main element, and they build 
extracellular matrix (ECM) proteins, such as collagen, elastin, smooth 
muscle actin and others, and, eventually, new tissue. Cells are obtained 
from living tissue through biopsies or through tissue parts that are no 
longer needed such as umbilical cords. The cell type that is implemented 
usually corresponds to the type of tissue that will be created: 
keratinocytes for skin TE, cardiomyocytes for cardiac TE, osteoblasts for 
bone TE etc. 
The scaffold is the supporting structure that gives the two- or three-
dimensional form to the construct and supports it in its growing phase. 
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Furthermore, scaffolds interact with the cells and affect their 
proliferation and differentiation rate and they allow space for new tissue 
formation including vascularisation [Chan & Leong 2008]. Ideally, 
scaffolds should be biodegradable, meaning that they should gradually 
decompose so that eventually an exogenous-material-free tissue will 
remain [Ratner & Bryant 2004; Patel & Fisher 2008].  
Choosing the correct material for a scaffold is a science in itself. The 
selection is very wide and the parameters that need to be considered 
likewise. Scaffolds may be naturally occurring ones, such as collagen, 
fibrin, hyaluronan and others, that exhibit better biocompatibility and 
provide a natural environment that may promote cell adhesion, cell-cell 
communication and the production of new ECM or synthetic ones, whose 
properties can be tailored according to each application. In such 
materials surface modifications occur often in order to improve 
biocompatibility. 
Load bearing applications such as bone and cartilage TE require materials 
with good mechanical properties, such as ceramics (calcium phosphates 
and carbonates and others) and synthetic polymers (poly methyl 
methacrylate – PMMA, polyurethane and others) [Place et al. 2009]. 
Polymers come in a wide range, both biodegradable and not. Polylactic 
and polyglycolic acids as well as polycaprolactone are biodegradable 
materials that are widely used in vascular TE while ePTFE (expanded 
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polytetrafluoroethylene) is a non-biodegradable polymer that has been 
shown to promote endothelialisation with the use of different coatings 
[Ravi & Chaikof 2010]. 
A very interesting category of scaffolds are hydrogels. Hydrogels are 3D 
cross-linked insoluble, hydrophilic networks of polymers that are 
populated with cells prior to polymerisation. Natural hydrogels can be 
made of collagen and fibrin and they exhibit high biocompatibility. A 
main advantage of hydrogels is that they can be injected in any possible 
form, making them good candidates for complicated tissue geometries 
such as heart valves or for direct in vivo injection for cell or drug delivery 
[Jockenhoevel et al. 2001; Geckil et al. 2010; Nguyen & Lee 2010]. 
 Decellularised matrices are tissue parts that undergo a decellularisation 
procedure during which all the cellular material is removed with the use 
of detergents. The resulting scaffold contains pre-existing ECM that can 
be newly seeded with cells. The new construct is usually used to replace 
the same type of tissue as the original, but not necessarily. There are 
reports of decellularised scaffolds in heart valve, blood vessel, nerve and 
ligament TE [Chan & Leong 2008]. 
The chosen material is seeded with cells, which proliferate, build ECM 
proteins and create a composite cell-scaffold TE-construct. The contact 
with the biomaterial provides an important external stimulus that may 
promote cell-cell communication and proliferation or may inhibit it. 
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Stimuli are crucial for cell development. Without them, cells gradually 
lose their properties and dedifferentiate [Schnabel et al. 2002; Lacorre et 
al. 2004; Zhang et al. 2010]. This interdependency of biomaterials and 
cells makes the system even more interesting. 
In order to keep the cells fit and improve the mechanical properties of 
the TE-construct, external stimuli in the form of pressure, strain or stress 
can be applied. Depending on the type of tissue that is being grown, 
different forms of stimuli can bring the desired results. Several groups 
applied cyclic strains on smooth muscle cell based constructs and 
observed significant increase on the production of smooth muscle myosin 
and smooth muscle actin, the two most important proteins of this kind of 
tissue [Owens 1996; Reusch et al. 1996; Candiani et al. 2010]. Gilbert et 
al. also demonstrated that increasing the frequency of cyclic stretching 
also increases the production of smooth muscle actin [Gilbert et al. 
2007]. Furthermore, cyclic strain was associated with an increase in cell 
proliferation, in a study made on rat vascular smooth muscle cells grown 
on silicone elastomeric plates [Wilson et al. 1993] while Cummings et al. 
showed that the same type of cells, when grown in fibrin and collagen 
matrices, with cyclic strain, result in tissue that has reduced proliferation 
rate, but increased mechanical properties such as linear modulus, tensile 
strength and toughness [Cummings et al. 2004].  
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There are also numerous reports that mechanical conditioning 
significantly promotes collagen synthesis. There are several different 
types of collagen, but collagen I, the basic component of connective 
tissue, is the most abundant protein in humans, comprising 
approximately 1/3 of the total body protein content [Reddy & Enwemeka 
1996; Di Lullo et al. 2002]. As a result, collagen has been in the focus of 
various research groups and especially the ones dealing with 
cardiovascular TE, as increased collagen content is closely connected to 
improved mechanical properties, and the cardiovascular system is a 
system that is under pulsatile pressure 24 hours a day. 
 
1.3 Cardiovascular Disease and Treatment Methods 
 
The heart is providing approximately 80 ml of blood per pulse (male 
adults) and it pulsates approximately 70 times per minute [Despopoulos 
& Silbernagl 2001]. This amounts to 5600 ml of blood per minute, 2900 
m
3
 in a year and some 200.000 m
3
 in a lifetime, more than one and a half 
times the entire volume of the Titanic. The heart pumps blood through a 
system of blood vessels, which provides oxygen to all organs of the 
human body, including the heart itself. Cessation of blood flow for a 
matter of minutes equals death. According to data published by the 
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World Health Organisation in 2004, concerning the status of its members 
in 2002, cardiovascular disease is the leading cause for death worldwide, 
not only in the developed, but also in the developing world [WHO 2004].  
During the past two centuries, a plethora of scientists have worked 
towards the aim of treating cardiovascular disease and impressive 
discoveries and inventions have made their way from laboratory to 
clinical practice. The golden standard for the treatment of coronary 
artery disease has been since 1957 the coronary artery bypass graft 
surgery (CABG)[Livesay 2004]. CABG includes the transplantation of a 
blood vessel segment from one part of the body (usually the saphenous 
vein) to the coronary artery of the heart in order to replace occluded 
parts of vessels.  
The other major technique in this field was introduced in 1977 by 
Andreas Gruntzig in Zurich [Gruntzig 1978]. A catheter with a small 
balloon at its tip was inserted at the site of the arterial stenosis and the 
balloon was inflated, compressing the atherosclerotic material to the 
sides. That was the first angioplasty procedure in history [Mehta & Khan 
2002]. The method has since then undergone major modifications and 
improvements. In order to keep the artery open, a plastic or metallic 
cylindrical structure in the form of a mesh, termed stent, was introduced 
in the treated site. The first stent operation took place in 1986 and 17 
years later drug eluting stents (DES) were accepted by the United States 
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Food and Drug Administration (FDA) and introduced to clinical practice 
[Meier et al. 2003; Bajaj et al. 2010]. These are stents that can elute a 
special drug in order to inhibit stent restenosis.  
These methods have doubtless saved innumerable lives, but they are still 
far from perfect. Studies performed in 2000 and 2010 showed that both 
CABG and angioplasty exhibit a 10-14% mortality rate at 7 years from 
intervention [Feit et al. 2000; Nikolov et al. 2010]. A meta-analysis carried 
out in 2007 showed 5% mortality at 10 months from intervention for 
patients of coronary artery disease undergoing DES treatment [Biondi-
Zoccai et al. 2008]. DES treatments have been reported to carry an 
additional risk, that of the formation of aneurysms, which are then 
further treated with other methods [Bajaj et al. 2010]. Thus, the 
cardiovascular system is considered a good candidate for TE. 
 
1.4 Cardiovascular Tissue Engineering 
 
For more than 20 years several research groups have been trying to 
create TE-vascular grafts, heart valves, cardiac tissue and pericardium 
using a variety of methods and materials [Weinberg & Bell 1986; 
Flanagan & Pandit 2003; Giraud et al. 2007; Veggian et al. 2007; Tschoeke 
et al. 2008]. Collagen and fibrin gel scaffolds are among the most popular 
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due to their biological nature and their ability to be moulded, which can 
easily produce an endless variety of shapes. Plain sheets of cells are also 
used in vascular TE in order to avoid the introduction of foreign materials 
and to easily fabricate several cell layers which can be rolled and create a 
cylindrical geometry. Different cell types are also used, to mimic the 
physiological anatomy of blood vessels [L'Heureux et al. 1998; Ratcliffe 
2000]. Biodegradable scaffold materials such as polyglycolic acid or 
polylactide are another solution towards completely autologous 
prestheses [Niklason et al. 1999; Tschoeke et al. 2009]. Finally, there are 
several groups that prefer decellularised tissue scaffolds. This technique 
is about explanting an animal organ or tissue and using detergents to 
remove all cellular material. The remaining tissue is made of ECM 
proteins, which can form an excellent scaffold for the seeding of new 
cells. A variation of this technique is the production of xenogenic 
constructs in the desired geometry that are decellularised and reseeded 
with autologous cells [Leyh et al. 2003; Stegemann et al. 2007]. 
The cardiovascular system is constantly under pulsatile pressure and 
cardiovascular TE-implants should be able to withstand it and function 
correctly under this pressure. Mechanical conditioning is therefore of 
utmost importance. Collagen production is one key element to durable 
vessels and pulsatile flow, tensile strength and strain and cyclic flexure 
were found to greatly enhance its production [Trachslin et al. 1999; 
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Hoerstrup et al. 2001; Mironov et al. 2003; Engelmayr et al. 2005; 
Flanagan et al. 2007; Hahn et al. 2007]. Furthermore, the alignment of 
collagen fibres seems to play an important role in mechanical properties 
of cardiovascular constructs, as it was observed in the production of TE 
vascular grafts and heart valves [Jeong et al. 2007; Robinson et al. 2007]. 
In addition to increased collagen, pulsatile flow also resulted in 
accelerated proliferation of smooth muscle and endothelial cells which is 
another characteristic of viable vascular grafts [Jeong et al. 2004; 
Williams & Wick 2004]. 
The use of different types of scaffold materials and cell seeding 
techniques in combination with variable loading patterns that may 
include shear stress, tensile stress and pulsatile pressure can be fairly 
complicated and standard laboratory equipment and consumables are 
often insufficient. For this reason, the majority of research groups in 
cardiovascular tissue engineering assemble specialised systems that can 
perform all the necessary functions. These systems are termed bioreactor 
systems.  
 
1.5 Bioreactor Systems for Vascular Tissue Engineering 
 
The term bioreactor has been traditionally applied to large metallic 
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cylindrical vessels from the area of chemical or bioengineering that 
support biologically or chemically active environments [Mironov et al. 
2006]. The emergence of TE and its rising popularity has led to the 
adoption of the term and given it a new definition. A bioreactor or 
bioreactor system may perform some or all of the following functions: 
(a) Permit control of the environmental variables of the tissue, such 
as temperature, oxygen (O2), carbon dioxide (CO2) and pH. 
(b) Provide sufficient nutrients to the tissue and allow their waste 
removal. 
(c) Allow uniform three-dimensional cell seeding. 
(d) Enable aseptic operation and handling. 
(e) Offer efficient mass transfer through the tissue in order to induce 
shear stress. 
(f) Expose the TE construct to physical stimuli (mechanical and/or 
electrical). 
(g) Monitor the formation of tissue. 
(h) Encourage the proliferation of cells. 
[Barron et al. 2003; Portner et al. 2005; Bilodeau & Mantovani 2006; 
Chen & Hu 2006; Martin et al. 2008] 
The standard solution for the temperature control is the placement of the 
bioreactor system in an incubator, which implements an intrinsic 
automatic temperature control. The incubators are usually intended for 
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cell-culture and therefore include 5% CO2 in the environment. This 
facilitates the O2 and CO2 control, as gas permeable tubing will allow the 
gas exchange between bioreactor and incubator. Of course, more 
sophisticated systems that include O2, CO2 and pH sensors can provide a 
continuous monitoring and recording of these values for more accurate 
documentation [El-Kurdi et al. 2008]. 
One important element in the design of bioreactors for vascular TE, as 
already mentioned, is the ability to produce pulsatile pressure. In this 
way, mechanical stimuli in the form of pressure and shear stress are 
provided and the proliferation of cells is encouraged. Different solutions 
to control the pulsatile pressure have been proposed. Air pumps (i.e. 
mechanical ventilators) have been implemented, which can apply 
pressure pulses through a silicone membrane [Hoerstrup et al. 2001; 
Thompson et al. 2002; Flanagan et al. 2007; Ziegelmueller et al. 2010]. 
Another approach is to use a computer-controlled piston pump in order 
to create pulses [El-Kurdi et al. 2008; Lanzarone et al. 2009; Shaikh et al. 
2010]. This solution contains the risk of reaching a negative pressure that 
is connected with haemolysis, but it can deliver faster pressure regulation 
and more elaborate pulse profiles. 
Pulse profile is the form of the curve showing pressure over time and 
several groups have taken interest in generating physiological-like pulse 
profiles in their bioreactor systems. Thompson et al. [Thompson et al. 
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2002] used a mechanical ventilator with reasonably accurate results 
although the finer second peak, caused by the regurgitation of the aortic 
valve, is not expressed. Pulses with a steep peak, on the other hand, carry 
a higher risk of haemolytic effects due to very fast pressure drop 
[Lanzarone et al. 2009]. Another study observed lower cell proliferation 
and protein concentration due to the inappropriate, peaky pulse profile 
[Narita et al. 2004].  
Accurate pressure and flow monitoring is critical in bioreactor systems, 
because, in many cases, the constructs are in the beginning very fragile 
and pressure or shear stress peaks might lead to rupture of the tissue or 
to detachment of the cells. Several research groups use pressure sensors 
before and after the TE construct chamber, so that the pressure drop 
within the chamber can be evaluated and the correct pressure can be 
calculated [Mironov et al. 2003; El-Kurdi et al. 2008]. 
Complicated systems with automatic control circuits and numerous 
components are not always the best solution. Simpler systems are easier 
to assemble and operate and, very often, a good idea suffices for 
producing remarkable results. The easiest way to monitor the TE 
constructs is to design transparent elements that allow direct optical 
control. Dvir et al. designed a showerhead-like component that can 
create a homogenous, laminar flow and enables the accurate estimation 
of shear stress [Dvir et al. 2006]. Another idea, though, in order to grow 
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TE constructs in a physiological mimicking environment is to use an actual 
native physiological environment. Chue et al. used dog peritoneal and 
pleural cavities to grow TE vascular grafts with very good results [Chue et 
al. 2004].  
Although a living organism can easily fulfil the temperature, O2, CO2, pH 
and sterility requirements of bioreactors, monitoring of the tissue is 
somewhat more difficult lacking optical control. Optical control itself, 
whilst it is an excellent method for macroscopic observations, cannot 
provide accurate data on the mechanical properties of the tissue. Closer 
continuous monitoring of a key mechanical property of the vessel is very 
important to evaluate the development of the construct. Such a property 
that is associated to many cardiovascular disorders and to the good 
function of the vessel is its compliance. 
 
1.6 Compliance of Vascular Grafts 
 
Compliance is a characteristic of hollow organs and it is defined as the 
ratio of the change in volume to the pressure change: C=ΔV/ΔP. The 
measurement of the volume of an organ is a complicated procedure and 
the proposed formula from the International Organization for 
Standardization (ISO) is the following [ISO 1998a]: 
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% = 	
/		 × 10      (1.1) 
where: 
%C: Circumferential compliance in %/100mmHg  
p2: higher pressure value in mmHg 
p1: lower pressure value in mmHg 
Rp2: internal diameter under pressure p2 
Rp1: external diameter under pressure p1 
 
One of the most important conditions to which compliance is associated 
is the development of abdominal aortic aneurysms (AAA). AAA were 
correlated with an increase in the vessel compliance which decreased 
significantly [Rentschler & Baxter 2008; Long et al. 2009]. Another related 
disease is hypertension. Arterial stiffness which is an indication of 
hypertension can be quantified through compliance [Reneman & Hoeks 
1995; Laurent et al. 2003; Toussaint et al. 2009]. Besides clinical 
applications, compliance is already used in TE in order to monitor the 
development of vascular grafts and heart valves. A comparison between 
the values of the TE constructs and of native vessels can be a very good 
indicator of the maturation of the grafts [He & Matsuda 2002; 
Papaioannou et al. 2003; Dahl et al. 2007; Vismara et al. 2010]. Another 
use is in the evaluation of the intra-aortic balloon pump, a technique for 
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the mechanical assistance of a failing heart. A mock circulatory system 
was developed and compliance was used as an index to evaluate the 
efficiency of the method [Papaioannou et al. 2002; Papaioannou et al. 
2004]. One final example can be found in a study from 1992. Steward and 
Lyman examined the problems that could occur from a compliance 
mismatch between a vascular graft and a host vessel using an 
experimental setup. It suggested that a possible mismatch can lead to 
significant problems after implantation such as intimal hyperplasia and 
thrombosis [Stewart & Lyman 1992]. 
Compliance is measured in %/100mmHg, and the value is typically 
between 1 and 10. This means that a vessel diameter changes about 10% 
per 100 mmHg and the compliance is typically measured between 80 and 
120 mmHg, i.e. 40 mmHg pressure difference. This amounts, for a vessel 
of 5 mm in diameter, to a diameter change of 0,2 to 0,02 mm or even 
less. In order to measure such diameter changes under dynamic 
conditions, very accurate methods are needed. 
One of the first attempts to measure compliance was carried out by 
Peterson et al. in 1960. A strain transducer was used with a reported 
sensitivity of ±0,5 μm in order to measure the arterial compliance of 10 
dogs and the results, obtained with analogue and digital computers, were 
very successful [Peterson & Jensen 1960]. In more recent studies, when 
its value is measured in vivo this is done with high resolution ultrasound 
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or with MRI [Cambria et al. 1987; Chamiot-Clerc et al. 1998; Li et al. 
2008]. In the laboratory easier-to-use methods can also be implemented 
with high accuracy, such as digital imaging and video [Blondel et al. 2001; 
L'Heureux et al. 2006] and light or laser micrometers [Webb et al. 2007; 
Syedain et al. 2011]. A comparative study of different compliance 
measuring methods showed a similar accuracy and that the choice 
depends on each situation [Rajesh et al. 2007].  
 
1.7 Durability Testing of Vascular Grafts 
 
One important factor that one has to keep in mind while developing TE 
constructs is the procedures of acceptance to the clinical practice. TE 
implants are considered medical devices and therefore they need to fulfil 
certain specifications. ISO issues an international standard concerning the 
way mechanical testing on implants should be performed and the 
property requirements that the products need to achieve. In the United 
States FDA fulfils this role and it issues its own regulations.  
In the field of heart valves and stents where the use of artificial 
replacement is established, either with mechanical valves or 
decellularised xenografts, regulations concerning durability testing of the 
constructs exist. FDA requires 600 million cycles for rigid valves and 200 
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million cycles for flexible ones [FDA 2010]. This figures correspond to 16,3 
and 5,4 years respectively, at a physiological frequency. Accelerated 
testing can shorten the timeframe of such an investigation. The Canadian 
ministry of health publishes a similar guide concerning stents, in which it 
is mentioned that accelerated in-vitro testing of approximately 10 years 
of real life should be performed [Health-Canada 2004]. 
Biological vascular grafts are not yet in the daily clinical practice and the 
ISO regulation concerning their testing methods does not require 
durability testing [ISO 1998b]. Nevertheless, better vascular grafts are 
created every day and the technology will soon be mature enough to 
start clinical testing with humans (the study of L’Heureux in 2006 was 
performed on humans, [L'Heureux et al. 2006]). Durability testing will be 
then necessary and it is safe to assume that it will have similar 
requirements like heart valves and stents. 
A surprisingly small number of bioreactors that can apply pulses in higher 
frequencies exist and then only to simulate foetus development [Iwasaki 
et al. 2008]. Apart from durability testing, such bioreactors might also be 
able to perform accelerated conditioning of cardiovascular constructs and 
also prove very useful in cases that time is very important such as infants 
born with a vascular or heart valve insufficiency or patients in the waiting 
list for a CABG procedure. 
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1.8 Aim of the Study 
 
The aim of this study is the development of a vascular graft bioreactor 
system that fulfils the following requirements: 
(a) The system should be made of biocompatible and sterilisable 
materials and should be easy to assemble under sterile 
conditions. 
(b) It should allow the cultivation and the conditioning of a vascular 
graft under pulsatile conditions. 
(c) It should include the potential of continuous monitoring of O2, 
CO2 and pH. 
(d) Adjustable pressure pulse profiles should be easily feasible. 
(e) It should allow in-vitro compliance measurements. 
(f) It should allow the performance of accelerated conditioning and 
durability testing. 
Our hypothesis is that a custom made modular system, with computer 
controlled pressure pulses and monitoring of pressure and diameter of 
the graft can fulfil all the requirements, achieve the aims set and bring 
tissue engineered vascular grafts a step closer to clinical application.
2. Development 
 
2.1  Bioreactor System Development 
 
2.1.1 Overview 
A schematic overview of the final experimental setup of the system can 
be seen in figure 2.1.  
 
 
 
 
 
 
 
 
 
Figure 2.1: Overview of the system 
There are two circuits, the main one (continuous line) and the secondary 
one (including the dashed line). In the main circuit, there is a pulse-free 
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centrifugal pump (B) that receives medium from the reservoir (A) and 
pumps it through the vascular grafts which is placed in the vascular graft 
chamber (VGC) (E). The flow is monitored by two pressure sensors (D), 
before and after the VGC and by a flow sensor (G). Further down, the 
circuit branches out to the pulse chamber (F) which delivers pressure 
pulses to the system by means of a linear motor positioned above it. The 
last elements of the system are the tube clamps (C) which are used to 
add resistant to the circuit and raise the pressure in the part after the 
centrifugal pump.  
The secondary circuit is responsible for the perfusion of the outer surface 
of the vascular graft. It is branching out just after the pump, continues 
into the VGC and then returns to the main circuit (H), just before the 
reservoir.  
 
 
2.1.2 Pressure 
 
2.1.2.1 Pressure Calculations 
In order to understand the role of the tube clamps (figure 2.1, C), it is 
easier to examine the electrical analogue of the system (figure 2.2, A and 
B). 
2 | Development 
 
 
24 
 
 
 
 
 
 
 
 
 
In figure 2.2, A, the pump is represented by a voltage source V0, the 
vascular graft by the resistor R2, which cannot be adjusted and the first 
clamp is represented by the resistor R1 which is an adjustable resistor. R3 
represents all the remaining hydraulic resistance created by the rest of 
the circuit. The current I represents the flow Q, which is a given since it is 
the current we select to run around the system, by adjusting the 
resistance R1. Let’s assume that V0=100V, I=1A, R2=10Ω and R3=20Ω. Then 
we have the following: 
 =  ⇔  =  	⇔ 	 = 100	     (2.1) 
 
						 = ! + # + $ 	⇔ 	! = 70	     (2.2) 
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VR3 
Figure 2.2: Electrical Analogue of the system.  
R: Resistance, V: Voltage source 
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The voltage drops that correspond to the pressure drops of the actual 
system are depicted in the diagram of figure 2.3. By changing the R1, we 
can change the voltage between the points d and e, where the vascular 
graft is positioned (dashed line), but the current will change as well, since 
the total resistance Rtotal will also change. In other words, and moving 
back to the hydraulic system, the pressure in the vascular graft will 
depend on the flow through the system. 
 
Figure 2.3: Voltage diagram of the system in Figure 2.2A 
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Figure 2.4: Voltage diagram of the system in Figure 2.2B 
In order to ensure that flow and pressure can be adjusted independently, 
the circuit depicted in figure 2.2B can be used, where the resistance R4 is 
added, which represents a second tube clamp, after the vascular graft 
chamber. In this way, both resistances, R1 and R4 can be adjusted so that 
both the total resistance and the voltage at R2 have the desired values. 
The corresponding voltage diagram can be seen in figure 2.4. 
 
2.1.2.2 Circulator Pump 
A circulator pump is used for the circulation of the cell culture medium 
around the system in order to provide nutrients to the cells. The 
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circulator pump should be pulse-free, so that the pulses can be adjusted 
by the pulse generator (Chapter 2.1.2.3). Therefore, a peristaltic pump, 
such as the ones used in medical and laboratory practice, would not be 
suitable. A centrifugal pump rotating with sufficient revolutions per 
minute (rpm) and which can also be sterilized would fit the requirements. 
We selected the EHEIM Universal 1250 (EHEIM & Co GmbH, Deizisau, 
Germany), made of simple parts that can be assembled without the use 
of tools under the workbench and whose characteristics fit the 
application. The operation diagram of the pump as provided by the 
company can be seen in figure 2.5. By adjusting the two tube clamps we 
can achieve any pressure under the characteristic curve of the pump 
(shaded area). 
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Figure 2.5: Operation diagram of the pump EHEIM Universal 1250 
 
2.1.2.3 Pulsatile Pressure Chamber and Frames 
 
In order to create an exact pressure profile, we used a computer 
controlled pulse generator which delivers pressure pulses that are 
superimposed to the linear pressure created by the centrifugal pump. 
The pulse generator is composed by three main parts. The first one is a 
small chamber made of PMMA (figure 2.6, A) with a silicone membrane 
on its top part. This chamber is connected as a branch to the main circuit 
(figure 2.1, F) and is completely filled with cell culture medium. Above the 
chamber a voice-coil actuator is placed (figure 2.6, B). This is a linear 
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motor which can perform a vertical translation of its central shaft on 
which a piston is attached. The position of the piston and the force that is 
exerted on it depend on the current running the coil of the actuator. The 
current of the coil can be adjusted through a pc with a digital to analogue 
card and an amplifier. The piston comes in contact with the silicone 
membrane and applies pressure. The motor is placed above the chamber 
and is held to its position with a custom made aluminium frame (figure 
2.6, C).  
 
 
Figure 2.6: The Pulse Generator. (A) Pulse Chamber,  
(B) Voice-Coil Actuator, (C) Aluminium Frame 
C 
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The first tests were run using a prototype voice-coil actuator, developed 
in the Institute for Applied Medical Engineering by Thomas Finocchiaro. A 
custom frame was then developed that would keep the actuator fixed in 
the correct position with 4 screws (figure 2.7A, B). For the next version of 
the system, the need to have at least two systems running 
simultaneously in order to compare a static to a dynamically conditioned 
vessel was considered. Pulsation would be needed in both systems 
though in order to measure the compliance. Therefore, the frame shown 
in figures 2.7C and 2.7D was developed. This frame allows the easy 
montage of the actuator so that it can be quickly transferred from one 
system to the other. The top screws are attached on the frame and they 
only need to be loosened to let the motor, which is screwed on the top 
disc, detach with a short rotation. 
  
This new frame was made according to the actuator that was later used, 
a commercial model by the company Moeninghoff (Type 810.15, 
Maschinenfabrik Mönninghoff GmbH & Co.KG, Germany) that is used in 
the industry for high precision positioning systems. This model has a 
nominal force of 59,5 N (at a current of 4,2A). This force creates the 
pressure through the piston tip which has a total area of about 1,6 cm
2
. 
We can thus calculate the maximum pressure possible: 
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& = '( = )*,)!,, ∗ 10.000	&/ ≅ 372	3&/ = 3,72	4/5 = 2789889: (2.3) 
 
This pressure is more than enough for this application. This model was 
selected also because of its stroke of 10 mm (in comparison to the model 
810.13, that has a 5 mm stroke).  
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Figure 2.7: Aluminium frames. (A)-(B) Frame 1, (C)-(D) Frame 2 
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2.1.2.4 Pressure Sensors 
 
The pressure is measured before and after the vascular graft chamber 
(figure 2.1, D) in order to be able to assess the pressure drop through the 
vessel. The vessel is positioned between the two sensors, approximately, 
so that the mean value of the two signals should correspond to the real 
value. A good way to see the magnitude of the error is to check how big 
the difference between the two values is. A big difference corresponds to 
a big pressure drop inside the vessel and therefore a relatively big 
uncertainty concerning the value of the pressure on the point where its 
diameter is measured and, therefore, the compliance is calculated. If the 
difference is small, the real value of the pressure can vary within a small 
spectrum so that the result is more accurate. 
 
The pressure system used is called Xtrans from the company Codan 
(Codan pvb Critical Care GmbH, Germany). In this system, several sensors 
can be attached on a contact board which provides power and forwards 
the signal to the computer. It has a range of 0 to 350 mmHg. The sensors 
are calibrated with a pressure gauge prior to each experiment. The 
sensors can be cleaned and sterilized by plasma sterilisation in order to 
be reused. 
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2.1.3 Vascular Graft Chamber 
The vessel chamber (figure 2.1, E) is the chamber where the vascular graft 
is placed and through which the diameter of the vessel is measured and, 
subsequently, the compliance is calculated. The requirements of this 
chamber are the following: 
(a) luminal flow 
(b) outer surface flow 
(c) optical transparency for the measurement of the diameter 
(d) sterilisable materials 
(e) easy mounting of the vascular graft 
According to these requirements, the first vessel chamber was designed 
and constructed. 
 
2.1.3.1 Vascular Graft Chamber #1 
The first idea was to construct a single-part cylindrical chamber, which 
would be easy to clean, it would have good hydrodynamic behaviour and 
would require no assembly, but this idea was rejected due to the fact that 
a curved wall would cause a light refraction which would alter the 
measurement of the diameter. The next thought was to keep the single-
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part design, for simplicity, but make a rectangular chamber. This would 
mean that the material used would have to be transparent and 
sterilisable, properties that the widely used material poly (methyl 
methacrylate) (PMMA) has. The in-house scientific workshop advised us 
to avoid a single part PMMA bioreactor, because the transparency of the 
wall would be of low quality as a result of the use of machine tools. The 
best solution would be to use single parts for the sides, made of PMMA, 
and attach these to the main body of the chamber. 
The result was a chamber with a main body made of polyoxymethylene 
(POM) and the sides and the top part made of PMMA (figure 2.8A). The 
sides could be permanently attached to the main body, therefore they 
could be glued and the top part would have to be screwed on the main 
body. Two openings on the front and the rear side were created for the 
connectors where the vascular graft would be placed and which allowed a 
luminal flow. The connectors used were composed of 2 different parts for 
each side. One part was attached on the chamber with a screw-nut and 
the other part would clip on the first and it could be attached on the 
vessel (Colder Products Company GmbH, Mainz-Kastel, Germany).  
Two smaller openings, on the upper left part of one side and the lower 
right part of the opposite side were reserved for the flow at the outer 
surface of the vessel, with Luer-Lok connections. 
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The major drawback of this design was that the inner pressure of the 
chamber is acting against the side windows which resulted in leakage.  
 
2.1.3.2 Vascular Graft Chamber #2 
Since the glued windows were leaking, the chamber was redesigned and 
the side windows were screwed on the main body, like the top window. 
Silicone membranes were placed between the windows and the chamber 
(figure 2.8B) in order to seal it off.  
This solution was also flawed. The large area of contact between the 
membranes and the windows resulted in reduced pressure and leakage. 
Tightening the screws only resulted in excessive bending of the windows 
and breaking them. 
 
2.1.3.3 Vascular Graft Chamber #3 
In the third version, the silicone membranes were replaced with a silicone 
o-ring which were placed in special grooves at the sides and the top of 
the main body of the chamber. The o-rings were attached with medical 
grade silicone glue on the chamber. The top cover had 10 screws and 
each side 6. The chamber was sufficiently sealed while the system did not 
become more complex in comparison with version 2. 
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Figure 2.8: Vascular Graft Chambers. (A) Chamber #1,  
(B) Chamber #2, (C) Chamber#3 
 
2.1.3.4 Compliance Measurement Frame 
A problem that arose while calculating the compliance was that the 
vascular graft chamber was not fixed in a specific position and, as a result, 
the position where the optical micrometre measured the diameter could 
differ after the medium change or any other rearrangement of the 
elements of the system. This resulted to compliance values that were not 
C 
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comparable to each other, since they were made based on different cross 
sections. 
This problem had been solved with the construction of a small aluminium 
frame (figure 2.9A) where the vascular graft chamber is positioned (figure 
2.9B) and which was attached on the optical micrometre itself. Two 
channels where the screws are placed allow the translation along its main 
axis in order to find the desirable area of the vascular graft to be 
measured. 
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Figure 2.9: Compliance Measurement Frame 
 
2.1.4 Blood Gas Sensor Chamber and Frame 
In order to be able to monitor the value of the partial pressure of oxygen 
(pO2), the partial pressure of carbon dioxide (pCO2) and the pH, the 
B 
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respective sensors have been used (Mettler Toledo GmbH, Giessen, 
Germany). These sensors were mounted in a custom made chamber 
(figure 2.10A) that was supported by an aluminium frame (figure 2.10B). 
The requirements for the chamber were the following: 
(a) To provide housing for the Mettler Toledo blood gas sensors. 
(b) To create the least possible resistance to the flow. 
(c) To avoid the concentration of air bubbles that could alter the 
measurements. 
(d) To be made out of sterilisable materials. 
 
A 
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Figure 2.10: Blood Gas Measurement Chamber (A) and Frame (B) 
 
The chamber has 5 openings, three of which are used for the O2, the CO2 
and the pH sensors (from left to right, respectively, as seen in figure 
2.10B) and the other two are reserved for the future usage of other 
sensors such as glucose or lactate. Until then, they are sealed tightly with 
two lids. The rightmost part of the chamber is thicker because of the fact 
B 
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that the pH sensor needs to be deeper immersed in the fluid to function 
correctly.  
The size of the groove in the lower part where the cell culture medium 
flows has been selected so that the hydraulic diameter of the groove is 
equal to that of the connectors and the tube before it. 
In order to avoid the concentration of air bubbles, the chamber is 
attached to the frame with an angle of 30 degrees respective to the floor. 
The tips of the sensors reach the top part of the groove as well, so that no 
air cavities can be formed.  
The two main parts of the chamber were constructed of PMMA, because 
the transparency offers an additional advantage, that of visual control. 
The nozzles and the rings holding the sensors were made of polyether 
ether ketone (PEEK), because of its good mechanical properties. For the 
sealing, EPDM O-rings were used. The two parts are held together with 8 
screws that go completely through them and have screw nuts at their 
ends. Two screws more hold the complete chamber to the frame, while 
the blood gas sensors are also supported with custom made aluminium 
screw nuts. 
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2.1.5 Medium Reservoir 
 
The medium reservoir (figure 2.1, A) serves the purpose of supplying the 
pump with medium and of removing air bubbles from the system. It also 
works as a volume buffer and greatly facilitates the priming of the system 
with cell culture medium. 
 
Figure 2.11: Medium Reservoir 
 
The last version of this part (figure 2.11) has the following characteristics. 
It is made of PMMA which, again, allows the optical supervision of the 
medium flow, it has a silicone O-ring for sealing and the medium flows in 
and out through 2 PEEK nozzles. The inlet is located close to the top of 
the reservoir and the outlet close to the bottom. In addition, the angle 
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between the two nozzles is 60 degrees. Both of these elements were 
added so that no air bubbles enter the outlet nozzle and, subsequently, 
the pump. 
 
2.1.6 Flow Sensor 
A flow sensor is needed in order to monitor the flow of the circuit (figure 
2.1, G) for the following reasons: 
(a) High flow in the beginning of the cultivation period of a tissue 
engineered graft can tear the vessel apart. 
(b) Through the flow shear stress is applied on the cells and it is one 
of the important mechanical conditioning parameters that we 
wish to control, especially in combination with endothelial cells. 
(c) The cell culture medium transfers nutrients to the cells. If, due to 
the pressure profiles applied on the vascular graft, the flow is 
equal to zero, the cell growth will be affected. 
The flow meter that has been used is suitable for low flows (model Nr. 
82201117, Typ.01 Biotech B.I.O.-TECH, Vilshofen, Germany), starting 
from 15 ml/min until 3 l/min. For the low range (15 – 50 ml/min) a special 
nozzle is used. When the nozzle is attached, the maximum flow that the 
sensor can measure is 800 ml/min. With the nozzle attached, the 
resistance that the sensor introduces to the system is higher. 
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The fluid comes in contact only with the sensor housing and the turbine, 
both of which are made of biocompatible and sterilisable with plasma 
sterilisation materials. 
 
2.1.7 Tubing, Connectors and Consumables 
Silicone tubing (Tygon® Flexible Silicone Tubing T3310-23, Saint-Gobain 
Verneret, Paris, France) is used to connect the several parts of the circuit 
to each other. Silicone tubing allows the gas exchange with the 
environment and, since the complete setup is placed in an incubator, the 
tubing keeps the pCO2 and pO2 at physiological levels (18% O2 and 5% 
CO2). Two types of tubing are used, with an inner diameter of 8 and of 6,4 
mm. 
The connectors/nozzles for the reservoir, the pulse chamber and the 
blood gas sensor chamber, as it has already been mentioned, are made of 
PEEK. The connectors for the vascular graft chamber and the vascular 
graft itself are made of POM and stainless steel. The connectors are 
sterilisable through autoclaving. 
Several consumables are used in the bioreactor system, such as caps, 
syringes, sterile filters and Luer-Lok extensions. All of these materials are 
standard consumables used in clinical practice and they are one-use 
sterile items. The Luer-Lok extensions, more specifically, are used for the 
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secondary circuit that perfuses the outer surface of the vascular graft and 
for the connections to the pressure sensors. The extensions used have an 
inner diameter of 2 mm and are 40 and 100 cm long, respectively. 
 
2.1.8 Bioreactor System Assembly 
The system is designed so that it can be easily assembled under a sterile 
workbench, by two people. One person will keep his hands under the 
flow during the whole procedure, so that he can work sterile and the 
other person can hand him all the parts of the bioreactor and open the 
unsterile packaging. The procedure will be described in steps. All 
references made will be according to figure 2.12. 
(a) Person 1 puts on sterile gloves and lays a sterile drape on the 
workbench. 
(b) The main elements of the system are assembled. A sterile M4 
and M5 Allen key will be needed. The pump (B) and the pulse 
chamber (F) can be completely assembled while the reservoir (A) 
and the vascular graft chamber (E) should not have their lids 
tightly screwed, because they will be filled with medium. The 
blood has chamber (I) can be assembled together with the 
sensors. The aluminium frames of the vascular graft chamber, the 
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pulse chamber and the blood gas chamber do not need to be 
assembled in the workbench. 
(c) The silicone tubes are placed in the system to connect all parts 
together. The flow sensor (G) should also be placed on this step. 
The silicone tubes and the T-connectors where the secondary 
circuit branches out and where the pressure sensor tubes are 
attached can be sterilised in an assembled form so that less work 
need to be done in the uncomfortable sterile workbench 
environment (figure 2.12). 
(d) The thin tubing extensions are placed, together with the three-
way corks. The three-way corks are placed on the beginning and 
the end of the secondary circuit  (one at the branch after the 
pump and one at the branch before the reservoir) and one is 
placed on the back side of the pulse chamber. The pressure 
sensors (D) are also placed now. Two syringes are placed at the 
back openings of the pressure sensors. Luer-Lok lids should cover 
all remaining open ends, so that, apart from the reservoir and the 
vascular graft chamber, the system should be completely closed. 
(e) The vascular graft, either tissue engineered or native, is then 
attached to the inner connectors and it is fixed either with sterile 
cable straps or with sterile chirurgical thread. The inner 
connectors are then inserted between the outer connectors, in 
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the inside of the vascular graft chamber. If the vessel is shorter 
than the maximum length of the chamber, a third inner 
connector can be connected with a piece of tubing between the 
existing inner and the corresponding outer connector. This 
method is also used to stretch the vessel. 
(f) The vascular chamber is then filled with bioreactor medium. 
Person 2 should do that, with a 50 ml sterile pipette. The 
chamber volume is approximately 300ml. After that, the chamber 
is closed and screwed tightly. 
(g) The reservoir is filled last, two times. After the first filling, the 
reservoir should be slightly raised so that the tubes, the pump, 
the blood gas chamber and the pulse chamber are filled with 
medium. The pulse chamber, since it is located on a branch of the 
main circuit, should have its backside opening, via the three way 
cork, opened and when it is filled with medium closed again. The 
extensions of the pressure sensors are filled by pulling with the 
syringes while opening the pressure sensor valves. After that, the 
reservoir is filled again and it is closed tightly. The medium should 
be enough to fill the parts that were not filled before and the 
reservoir should still be half full after that. The reservoir has a 
volume of approximately 200 ml, so the cell culture medium of 
the whole system should be about 700 ml. 
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(h) The system can then be placed on a plastic tray (or on an 
incubator shelf) and it can be transferred out of the sterile 
workbench. The frames of the blood gas chamber, the pulse 
chamber and the vascular graft chamber are attached. The 
vascular graft chamber frame should be adjusted to the length of 
the chamber and then it can be fixed on the optical micrometer. 
Before it is completely fixed, the desirable location for the 
measurement of the vessel diameter should be chosen (the 
frame can then slide on the optical micrometer). The actuator 
should also be positioned on the pulse generator frame. 
(i) Last step is the position of the tube clamps, one after the pump 
and the second after the pulse generator. The first should be 
almost entirely closed and the second completely open when the 
pump is turned on for the first time. This ensures a low pressure 
value in the vascular graft chamber. After a minute the pump 
should be turned off. This allows the pump to release the air that 
is trapped in the propeller. A bubble will be formed in the tube at 
the outlet of the pump. After a few seconds the pump can be 
turned on again. The adjustment of the clamps can follow when 
the control software is running and the pressure and the flow are 
visualised. 
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When the pump is connected, a test run should be performed in order to 
check the system for leakage.  
 
Figure 2.12: Assembled system under a sterile workbench. (A) Medium Reservoir, 
(B) Circulating pump, (C) Vascular Graft Chamber, (D) Pulse Chamber 
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Figure 2.13: Assembly of the Bioreactor System. (A) Medium Reservoir,  
(B) Circulating Pump, (D) Pressure sensors, (E) Vascular Graft Chamber,  
(F) Pulse Chamber, (G) Flow Meter, (I) Blood Gas Sensors Chamber 
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2.1.9 Medium Change 
In order to change the medium, an empty sterile glass bottle will be 
needed as well as an infusion lid, also sterile. 
(a) The empty bottle is filled with cell culture medium that has been 
heated up to 37 degrees. 
(b) The bioreactor system is disconnected from the monitoring 
system and is placed in the sterile workbench. 
(c) If the vascular graft is still very fragile, it shouldn’t be completely 
emptied because it will collapse under the under-pressure and it 
might be damaged. In that case, tube clamps are positioned 
before and after the vascular graft chamber on the main circuit. 
(d) A Luer-Lok tubing extension is placed on the third opening of the 
3-way cork at the beginning of the secondary circuit, with its 
closed outlet towards the pump and a sterile filter is positioned 
on the 3-way cork at the end of the secondary circuit. The other 
end of the tubing is held in an empty container, lower than the 
bioreactor system. First the secondary circuit is emptied. With a 
syringe a small quantity of medium is drawn and the 3-way cork 
where the filter is placed is turned so that air can enter the 
vascular graft chamber. When the vascular graft chamber and the 
whole secondary circuit are empty, both three way corks are 
turned so that their open sides are towards the primary circuit. 
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While the primary circuit is emptying, the 3-way cork at the back 
of the pulse chamber is opened, so that this chamber can also 
empty. 
(e) An infusion set is used to fill the system up. The sharp end is 
attached on the lid of the medium bottle and the other end is 
attached at the same position that the system was emptied from, 
in the previous step. The filter in the other 3-way cork is removed 
and the lid of the reservoir is unscrewed a bit so that the air can 
come out. The system is filled one circuit at a time: first the 
secondary, and then the primary, by isolating the secondary with 
the 3-way corks. While the primary is being filled, the pulse 
chamber is opened until it is also filled with medium. 
(f) When almost 700 ml are in the system, the infusion set is 
removed, the reservoir lid is screwed back in place tightly and the 
bioreactor system is placed back in the incubator.  
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2.2 Monitoring and Control 
 
2.2.1 Overview 
The commercial software National Instruments LabView 8.6 has been 
used to develop the programs to control the bioreactor system. The parts 
that were controlled are the following: 
(a) Pressure sensors: The pressure of two sensors was fed in the 
system, visualized and recorded (figure 2.14, C and F). 
(b) Blood gas sensors: The values of pO2, pCO2 and pH were also 
monitored (figure 2.14, G). 
(c) Flow sensor: The flow sensor turbine sent pulses that were 
translated into turns per minute and, consecutively, flow (figure 
2.14, D). 
(d) Optical Micrometre: The Keyence optical micrometre sent the 
data of the outer diameter of the vessel (figure 2.14, B). 
(e) Actuator Control: The actuator was the only element that 
received an output from the software, which controlled its 
motion (figure 2.14, A and E). 
Except the optical micrometre and the O2 sensor that are connected to 
the computer through the serial ports, the rest of the inputs and outputs 
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are performed with a USB connected analogue-digital transducer (USB 
DAQ 6009, National Instruments). This data acquisition system (DAQ) has 
8 single analogue-input channels and 2 analogue output channels and can 
be easily controlled with LabView.  
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Figure 2.14: Front Panel of 2 Control Software Versions. (A) Actuator Control, (B) 
Optical Micrometre Monitoring, (C) Pressure Measurement Amplification, (D) 
Flow Sensor, (E) Pulse Generator Window, (F) Pressure Monitoring Window, (G) 
Blood Sensors Monitoring 
A 
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Figure 2.15: Block Diagram of “ComplianceSystem-Version3c” LabView Program. 
(A) Flow Sensor Control, (B) Pulse Generator Control, (C) Pressure Sensors, (D) 
Optical Micrometre Control 
2.2.2 Pressure Monitoring 
The pressure sensors (Xtrans, Codan pvb Critical Care GmbH) are 
connected on a small plastic base with 4 pins, 2 for the pressure signal 
and 2 for power. The signal cables are connected to 2 analogue-input 
positions of the device in order to have a differential pressure input, 
which results to a more accurate measurement. The power is provided by 
5V output of the same device which is a very stable source and creates 
very low noise. The result, after the amplification performed in the 
software, is an accuracy of ±0,5 mmHg. 
The signal is read in the software and is split in order to process each 
device separately. Then, it is filtered, amplified and displayed on the 
monitor (figure 2.15, C and 2.14, F). The amplification can be adjusted 
from the front panel of the program (figure 2.14, C). A small loop in the 
source serves to provide us with a “set to zero” function”, in order to set 
the reference level for each pressure sensor. 
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2.2.3 Blood Gas Monitoring 
 
Figure 2.16: Block Diagram of “Allin1v5-1” LabView Program.  
(A) Pressure, flow, CO2 and pH sensors, (B) O2 sensor 
 
Blood gas monitoring was not included in all experiments, because of the 
necessity to run parallel experiments under the same conditions, i.e. in 
the same incubator. The absence of the blood gas chamber and frame 
allows the system to fit in one standard incubator shelf and, 
subsequently, the placement of two systems in one incubator. The blood 
gas analysis is then performed manually, with an external device (blood 
gas analyser). 
Figure 2.16 presents the block diagram of an earlier version of the 
software. On figure 2.16, A the signals from the pressure sensor, the CO2 
A 
B 
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sensor, the pH sensor and the flow meter are all input signals of the DAQ. 
The signal is split and the data are converted to text string and are saved 
in a data file. The CO2 and pH sensors create a current signal that is 
converted to voltage with a resistance before it is read with the DAQ.  
The oxygen sensor is connected to the serial port (COM port) and its 
value is imported in LabView through a “Virtual Instrument Software 
Architecture” (VISA) element, which is the general element to control 
serial and parallel ports. The signal is imported and then the part of the 
information that interests us is selected, displayed and then converted to 
text string and saved into the data file. 
 
2.2.4 Flow Sensor Monitoring 
The flow sensor used is a turbine flow sensor. This means that it contains 
a small rotor that rotates faster when the flow is higher. Each rotation 
represents an amount of flow and it sends a voltage pulse as a signal. 
Measuring the frequency of these voltage pulses, allows us to monitor 
the flow. Figure 2.15, A contains the part of the code that is used to 
calculate the frequency of the pulses. The intrinsic functions of LabView 
for the calculation of the frequency of the signal did not result in a 
satisfactory measurement, thus the code of figure 2.15, A was written. 
The second and the third parts of the code are dedicated to the 
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calculation of the maximum and minimum value of the pulses, every 
second. According to these values, the first part of the code measures 
how many pulses occur every second and then the value of the flow is 
calculated. This method performs very well, with one minor shortcoming. 
Since it measures pulses per 1 second, it can only show integer values of 
the frequency. This results to the following error. The sensor creates 
p=2,5 pulses/ml. If we have a flow of f ml/min then the sensor will output 
p=2,5f pulses/min. Since we are measuring the pulses every second, we 
can divide with 60 and have p=0,042f pulses/s. In this figure, since we can 
only measure integers, we add a ±0,5 pulses/sec error. Therefore, we 
have: 
; = 0,042 ∙ > ± 0,5	;ABCDC/C    (2.4) 
where: 
p: pulses per second and 
f: flow in ml per minute 
 
Therefore, for a flow of 100ml/min, the error is about 12% and for 500 
ml/min it becomes 2,4%, which is sufficient for this application. For 
higher accuracy it is possible to measure the pulses for 10 continuous 
seconds and divide by 10. This would give us an accuracy of ±0,1 pulses/s. 
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2.2.5 Diameter Measurement 
The optical micrometer is also connected through a serial port and it, 
therefore, requires a VISA LabView element (figure 2.15, D). The 
micrometer emits, among other information, the value of the diameter of 
the vascular graft in millimetres with a frequency of 100 Hz. As in the case 
of the oxygen sensor, the part of the data with the diameter value is 
selected, it is displayed and then saved in the data file, together with the 
pressure, the time and the other parameters. 
 
2.2.6 Actuator Control 
The actuator is controlled through the analogue output of the DAQ. The 
signal is fed in a motor amplifier (DA 4303, Electrocraft ®, Germany) and 
then it is used to control the actuator. The amplifier also receives external 
power. 
The signal profile that is created in LabView used the Gaussian function: 
>EFG = / ∙ DEHIJGK      (2.5) 
This function has a Gaussian curve as a graph (figure 2.17, A). Parameter 
α defines the maximum height of the curve, parameter b its centre and 
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parameter c its width. By summing several functions, more complicated 
forms can be created (figure 2.17, B). 
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Figure 2.17: Curves created with the equation 2.5 
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 In figure 2.16A, a curve with α=5, b=10 and c=10 can be seen, while in 
figure 2.16B, 4 equations have been summed with the following 
parameters: 
 
 Parameter a Parameter b Parameter c 
Function 1 33 1,5 0,05 
Function 2 11 1,7 0,2 
Function 3 4 2,4 0,005 
Function 4 12 2,6 1 
    
Table 2.1: Parameters of the equations of the graph of figure 2.16B 
 
The signal that is used in the program is composed by 4 equations and all 
the parameters are adjustable in real time. The part of the block diagram 
that serves this purpose can be seen in figure 2.15, B while the controls of 
the front panel are in figure 2.14, A. An amplification adjuster is also 
added, before the signal proceeds to the amplifier and then to the 
actuator. 
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2.2.7 Automatically Controlled Valve 
In the attempt to automate the control of the pressure, an automatically 
controlled valve has been developed which is intended to replace the 
tube clamps (figure 2.1, C) that are used to increase the hydraulic 
resistance of the circuit. The automatic valve creates a variable hydraulic 
resistance by changing the cross sectional area of the tubing.  An electric 
motor rotating at 1,5 rpm (figure 2.18, Maxon Motors GmbH) drives the 
single axis translation of an inner cylinder at a speed of 1,5 mm/min 
through a screw thread connection. The inner cylinder moves within an 
outer cylinder which forms the housing of the valve and compresses the 
tubing reducing the cross sectional area available for the flow of the fluid, 
increasing the hydraulic resistance of the system. The motor is controlled 
through a NI LabView application and receives the pressure value from 
the pressure sensor as a feedback. It is then activated in 2 second cycles 
with 3 second pause between every two cycles in order to finely adjust 
the pressure of the system. The automatically controlled valve is very 
useful to maintain a desired pressure value for a conditioning or a 
mechanical testing process against possible pressure changes (e.g. due to 
tissue remodelling, temperature difference or accidental external 
interference). The time and the parameters of the activation of the 
mechanism are recorded in LabView in order to be analysed and to 
determine the nature of a possible problem or malfunction of the 
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bioreactor system. The screw thread, the inner and the outer cylinder 
were designed in Pro Engineer 5.0 and were manufactured in the in-
house scientific workshop. The valve is made of aluminium. 
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Figure 2.18: The Automatically Controlled Valve. The tube goes through an 
opening which is controlled by a motor. The motor receives the pressure value as 
a feedback in order to be activated. (A) Motor, (B) Tubing, (C) Inner Cylinder, (D) 
Variable Cross Sectional Area, (E) Outer Cylinder 
 
B 
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2.3 Mechanical Testing 
 
2.3.1 Burst Strength Chamber and Measurement 
A burst strength test is performed by applying pressure on a tissue 
sample and by raising it until the point that the tissue bursts. The 
pressure is monitored and the highest value recorded is the burst 
strength pressure of the tissue.  
In order to perform such tests, we use a custom-developed chamber 
(figure 2.19). The main body of the chamber is made of aluminium and it 
has three openings. The small side opening is intended for the application 
of pressure, the larger opening is where the pressure sensor is connected 
and the top opening is where the tissue sample is placed. There are two 
O-rings. The white flat O-ring is where the tissue is placed and on top of it 
comes the smaller red O-ring. The chamber is sealed tight with an 
aluminium lid which is screwed into place with 3 screws. The lid is 
composed by two pieces, the main lid and a smaller ring (light grey 
coloured in the picture) that is positioned under the main lid. Its original 
purpose was to be easily exchangeable with rings that have openings of 
different sizes, for the measurement of smaller and larger tissue samples. 
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This idea was abandoned, in order to have easier comparable results 
between all tests. The ring with an opening of 8mm in diameter is used. 
 
Figure 2.19: The burst strength chamber 
The burst strength pressure sensor (Jumo, Midas, type 401001/000, 
JUMO GmbH & Co. KG, Fulda, Germany) has a wider range than the 
sensors used in the vascular graft chamber, from 0 to 10 bar. This sensor 
creates a current signal which is converted to voltage with a resistance. It 
is then digitised through a DAQ (NI 6024E, National Instruments) and 
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processed by a LabView application that filters, amplifies and displays the 
signal. The pressure curve and its maximum value are also saved in a file. 
 
2.3.2 Tensile Strength Testing 
The tensile strength of vascular grafts is measured in a specialised 
machine (zwicki-Line Z2.5, Zwick GmbH&Co, Germany). It is possible to 
mount the whole vessel, by attaching it on metallic connectors and fixing 
the connectors on the clamps of the machine, or to test just a small 
sample of the tissue. In the latter case, both orientations, axial and radial, 
of the vessel can be tested. The tissue is then fixed directly on special 
clamps. The software of the machine records the stress-strain curve of 
the material and can calculate several other parameters such as the 
Young module, the maximum stress and strain or the total energy 
absorbed until the failure of the vessel. 
 
2.3.3 Suture Retention Strength Testing 
 
In a similar way like tensile strength, the suture retention strength of a 
vessel or of a tissue sample can be measured with the same equipment. 
The vessel or a tissue sample can be mounted on one side on the 
machine and on the other side a chirurgical thread pierces the vessel 
about half a centimetre from its edge and is fixed on the machine with 
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special clamps that inhibit the slipping of the vessel. The test is 
completed when the thread has completely torn the edge of the vessel. 
All tensile-strength related parameters can again be recorded. The actual 
stress applied on the vessel can be calculated by knowing the thickness of 
the thread and the vessel walls. 
 
2.3.4 Compliance Measurement 
The compliance of a hollow organ is defined as the ratio of the change in 
volume of the organ to the change in pressure which causes it: 
 = LLM      (2.6) 
 
Compliance has units of volume divided by pressure (e.g. ml/mmHg) 
In reality, the definition that is much more often used is that of the 
circumferential compliance (CC) or the ratio of the relative change in 
diameter of a vessel to the change in pressure which causes it: 
NOPN = QRR	LM ∙ 100%    (2.7) 
 
In equation 2.7, R1 is the diameter of the vessel in the diastolic phase. The 
units for CC are %/mmHg or %/100mmHg, in order to end up with a 
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figure between 0 and 10. CC is easier to measure since it requires just the 
diameter of the vessel and not the whole volume.  
The CC of a vessel can be measured either dynamically or statically. By 
dynamically it is meant that the CC is calculated while pressure pulses are 
applied on the vessel. The change in diameter of a native vessel under a 
pressure level of 80 to 120 mmHg is usually in the order of hundredths of 
millimetres. Therefore, the frequency of the pulses makes a very big 
difference since a high pulse frequency doesn’t allow enough time to the 
vessel to reach the maxima and the minima and the CC can differ greatly. 
The static measurement means that no pulses are applied and the 
pressure of the system is adjusted at 80 and 120 mmHg (or the values 
that are used for the calculation) and at each pressure the system is 
allowed time to come to an equilibrium after which the value of the 
diameter is recorded. This method has resulted to more accurate and 
reproducible measurement of the CC. 
An element which is essential for the reproducibility of diameter 
measurements of the vessel is the metallic frame that attaches the 
optical micrometre to the Vascular Graft Chamber (see paragraph 
2.1.3.4). 
Another important characteristic that should be taken into account is the 
outer pressure of the graft. The secondary circuit that provides the flow 
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around the graft, inside the VGC, acts as counter pressure during the 
compliance measurement. The three way cork that branches out after 
the pump should be closed so that the chamber is connected only to the 
low pressure part of the system near the medium reservoir. The add-on 
of a sterile filter on the opening of the reservoir brings this part of the 
system to atmospheric pressure. 
3. Materials and Methods 
 
3.1 Cell Culture  
 
3.1.1 Cell Isolation 
Cell culture is very often considered a trivial part of tissue engineering 
experiments but unless it is performed with care and consistency, it can 
lead to serious problems. Cell culture starts with cell isolation. 
Myofibroblasts are isolated from ovine carotid arteries and human and 
ovine umbilical cord arteries. The vessel is placed in a glass petri dish 
under the sterile workbench with 10-20 ml PBS in order for the cells not 
to dry out. In the case of umbilical cords, the artery has to be identified 
and isolated from the rest of the tissue. Then the outer layer of the 
vessel, the adventitia, is removed with sterile tweezers, because when 
the vessel is complete the migration of the cells to the cell culture flask 
requires longer time. The vessel is washed with PBS so that the remaining 
blood is removed. Then it is chopped in small pieces (2 mm in length) and 
the pieces are placed in cell culture flasks. Usually one artery is enough 
for one or two T-75 flasks. 10 ml of DMEM cell culture medium is added 
and the flasks are placed in the incubator. After 1-2 weeks, depending on 
the migration of myofibroblasts, the tissue pieces are removed and the 
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cells are cultivated for up to 1 week more, in order to reach confluence. 
Endothelial cells might also migrate, but the cultivation conditions (2-d 
culture) and the culture medium do not favour their proliferation. 
 
3.1.2 Medium Change 
Cells are cultured in T-75, T-125 and triple flasks. The first two kinds have 
the very important advantage that they can be handled with pipettes and 
no tilting of the flasks to change medium is necessary. They only have one 
level which allows us to be able to visually observe the entire population 
of the cells. The exact opposite advantages and disadvantages exist in the 
case of triple flasks. Cell feeding requires tilting of the flasks to dispose of 
the old medium which always involves a higher risk of contamination and 
only the lowest level can be observed under a microscope. On the other 
hand, they have 3 times the surface of a T-125 flask while being much 
more compact than 3 T-125 flasks. The cells can be fed much faster than 
the time required to feed 3 T-125 or 5 T-75 flasks. Therefore, the triple 
flasks are used in the last passages of the culture, when a high number of 
cells have to be fed. The higher risk for contamination is accepted in 
order to save time and space. 
Another practice in the Tissue Engineering and Biomaterials Group are 
the sterile controls for the cell culture medium. These are usually T-25 
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flasks that receive approximately 3 ml of medium, after the medium has 
been supplemented with the necessary substances. Depending on the 
cell type and the application, several different supplements can be used. 
The control is placed in an incubator 2-3 days before the medium will be 
used. Because of the small quantity and the favourable conditions, any 
contaminations will progress much faster in the control than in the 
medium bottle, stored in the refrigerator, and contaminated samples of 
supplements can be discovered and removed. 
 
3.1.3 Cell Passaging 
The first step of cell splitting is the aspiration of the cells culture medium 
and the washing of the cells with 5 ml of phosphate buffered saline (PBS) 
(half as much as the cell culture medium), because foetal calf serum 
(FCS), a standard supplement of cell culture medium, is a trypsin 
inhibitor. Then, the PBS is aspirated and the cells are handled with trypsin 
(about 2,5 ml/75 cm
2
 of surface) for 5 minutes in an incubator. When the 
cells have detached 10 ml of bioreactor medium per flask are added in 
order to stop the trypsinisation and the cells are transferred to new flasks 
according to the splitting ratio. Ratios of 1:1 (for primary cell culture) up 
to 1:3 are usually used. 
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Cell passaging, like changing of cell culture medium, is performed better 
in single layer flasks, such as T-75 and T-125. This is because after 
handling the cells with trypsin for 5 minutes, a pipette can be used to 
wash them off the surface with a small quantity of cell culture medium, 
so that more cells can be harvested from a flask, cell agglomerates will be 
broken and the cells will be equally spread in the new flask. The 
contamination risk is also lower, since no intermediate sterile vessel such 
as a falcon tube or a urine cup is needed.  Nevertheless, triple flasks are 
very useful in the case of mass-cell culture. 
  
3.1.4 Cell Harvesting 
Successful cell harvesting requires in the beginning the same technique 
like cell splitting. As many cells as possible have to detach from the 
surface of the flask and the cell clumps should be broken so that in the 
end we will have a homogeneous solution with cells uniformly spread in 
it. The next step after the handling with trypsin of the cells is the 
centrifugation. Cells are centrifuged for 5 minutes at an acceleration of 
500 g. Then, the supernatant is aspirated and the cells are resuspended in 
a buffer solution (usually tris-buffered-saline, TBS, is used). The cell 
number is usually determined before centrifugation, so that they are not 
so dense. Alternatively, it can be done afterwards with dilution of a small 
sample of cells in TBS.  
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3.2 Tissue Engineering of Vascular Grafts 
 
3.2.1 Overview 
The vascular grafts that were created in the course of this work were 
based on fibrin gel. The technique is schematically presented in figure 
3.1. 
 
 
 
 
 
 
 
 
 
 
Cells are isolated from the patient with a biopsy. Myofibroblasts and 
endothelial cells are the types that are more commonly used. Blood is 
Whole Blood 
Cell Isolation 
through a Biopsy 
Fibrinogen and 
Thrombin 
Macroporous 
Mesh Patient 
Bioreactor 
Conditioning 
Tissue Engineered 
Vascular Graft 
Figure 3.1: Tissue Engineering of Vascular Grafts 
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also needed in order to isolate two proteins: fibrinogen and thrombin. An 
aqueous solution is then created with the aforementioned proteins, the 
cells and calcium chloride (CaCl2). The solution fills a mould and after a 
few minutes it is polymerised. The mould is gently removed and the 
tissue engineered vascular graft is ready. The next step required its 
conditioning statically and dynamically, under pulsatile pressure, in order 
to improve its mechanical properties and when it is stable and strong 
enough, it is implanted back to the patient. 
 
3.2.2 Preparation of Fibrinogen 
Fibrinogen can be isolated directly from the blood of the patient and this 
is the ultimate goal, in order to achieve autologous vascular grafts. In the 
phase of research and testing, mostly commercial fibrinogen is used, 
either from human or from sheep plasma (plasminogen free, Fluka GmbH 
or Sigma-Aldrich GmbH, Germany). Fibrinogen is first dissolved in distilled 
water in the appropriate concentration in order to achieve the desirable 
end-concentration. This takes place in a covered vessel such as a 6-well 
plate or a Petri-dish. The vessel should not be covered immediately 
though, because fibrinogen tends to stick to the lid due to static 
electricity. After 45 minutes, in order for it to completely dissolve, it is 
transferred in 6000 MW dialysis tubing and is dialysed overnight against 
TBS (1:1000) that has been adjusted to pH of 7,4.  
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On the next day, it is sterilised by filtration with 0,22 μm pore filters and 
its concentration is determined by light absorption at 280 nm. The final 
concentration is adjusted with the addition of sterile TBS.  
For an end-concentration of 10 mg/ml, which is a typical fibrinogen 
concentration for the TE constructs, a starting concentration of 25 mg/ml 
of distilled water is necessary in the case of human plasma, and 
somewhat lower, 20 mg/ml, in the case of sheep plasma fibrinogen. 
 
3.2.3 Preparation of Fibrin Gel 
Fibrin gel is composed, according to the protocol used in TEB, by 4 
components. 50% of the volume is fibrinogen, prepared as described in 
the previous paragraph, 35% is TBS that contains the harvested cells, 
approximately 10 million cells per ml, 7,5% is thrombin, the other protein 
needed for the polymerisation of the fibrin gel and the rest 7,5% is a 
sterile calcium chloride (CaCl2) solution at a concentration of 50 mM. 
CaCl2 inhibits the degradation of the gel and its concentration can be 
adjusted according to the needs.  
The two components that polymerise are fibrinogen and thrombin; 
therefore these should be mixed in the end. An easy way to prepare the 
gel is to have in one well plate thrombin together with TBS with cells and 
CaCl2 and in another one fibrinogen. The two can then be mixed 1:1 with 
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a double syringe system, so that they will be mixed well and they will not 
polymerise too early. About 3 seconds after the components have been 
mixed, polymerisation begins and they cannot be handled like liquids 
anymore. 45 minutes should be allowed for complete polymerisation. 
 
3.2.4 Moulding and Extraction 
Different moulds are used in the TEB for the fabrication of vascular grafts. 
For the preliminary tests of the system presented in this work, the 
procedure that is schematically described in figure 3.2 was used. 
 
 
 
 
 
 
 
 
 
 
3 | Materials and Methods 
 
 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mould consists of an outer hollow cylinder made of POM and an 
inner rod that can be attached inside, also made of POM. A macroporous 
polyvinylidene fluoride mesh (PVDF, provided by the Textiles Institute 
(Institut für Textiltechnik) of the RWTH Aachen) is also added to provide 
mechanical stability to the construct (figure 3.2A). The mesh is placed 
around the inner rod (figure 3.2B) and they are then dipped into sterilised 
sunflower oil to facilitate the extraction of the rod. Then, the rod and is 
placed inside the outer cylinder (figure 3.2C). The space between the 
Figure 3.2: Moulding and Extraction. (A) Inner and outer cylinder and 
Mesh, (B) Mesh around the inner cylinder, (C) Mould Assembly, (D) Mould 
filled with fibrin gel, (E) Tissue Engineered Vascular Graft. 
A B C 
D E 
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cylinder and the rod is then filled with the fibrin gel, as described in 
paragraph 3.2.3 and is left to polymerise for 45 minutes (figure 3.2D). The 
last step is the extraction of the gel (figure 3.2E). This is done very gently 
in order not to break the gel. First, the outer surface of the gel is 
detached from the outer cylinder with a thin metal pin. After that, the 
inner rod must be very slowly removed, with small rotating movements 
and by pulling it gently. The whole extraction process may well require 5 
or 10 minutes. 
 
3.2.5 Preparation of Porcine Carotid Arteries 
Porcine Carotid Arteries were kindly provided by the Animal Experiment 
Facility of the University Hospital Aachen and were placed in a sterile 
transport buffer solution (Appendix 7.1.4). The arteries were placed in 
bioreactor culture medium (Dulbecco’s Modified Eagle’s Medium, phenol 
red free, with 10% foetal calf serum, 1% antibiotic solution (10.000 
units/ml penicillin and 10.000 μg/ml streptomycin), 1% Glutamax (all 
from Gibco, Invitrogen GmbH, Darmstadt, Germany) and 1 M ascorbic 
acid (A8960, Sigma-Aldrich Chemie GmbH, Munich, Germany)) in a 
humidified cell culture incubator overnight prior to the experiment, in 
order to control the sterility of the grafts.  
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Once the bioreactor system is assembled, the vessels are prepared in 
order to be mounted in the bioreactor. Firstly they are placed in a glass 
petri-dish under the sterile workbench and bioreactor medium is added, 
so that the cells will not dry out. Then the outer layer of the vessel 
composed mostly of connective tissue is removed with sterile tweezers. 
This is done so that the vessel can be fixed to the connectors and so that 
its diameter is clearly defined in the optical micrometre. The vessel 
should be handled with care in order to avoid any damage. The 
procedure typically lasts about 30 minutes. A part of the prepared vessel 
is cut and is placed in bioreactor medium so that it will be fixed on the 
same day and it can be used as control. 
 
3.3 Analytical Methods 
 
3.3.1 Fixation and Paraffin Embedding of Tissue 
The protocols mentioned in the following paragraphs can be found in the 
Appendix (chapter 7.1). 
The first step in histology is to fix the tissue samples. To that end, we are 
using Carnoy’s solution, composed of ethanol, chloroform and acetic 
acid. Fixation time varies between half an hour and several hours, 
depending on the composition and thickness of the tissue. Fixed samples 
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need to be dehydrated in order to embed them to paraffin. Therefore 
they are immersed in a series of ethanol solutions with increasing 
concentration followed by xylol (xylene) and paraffin. Each step requires 
one hour. Next follows the paraffin embedding of the samples. Liquid 
paraffin fills small metallic moulds and then it is left to cold down. After 
some time, the moulds are removed and the paraffin blocks are ready for 
cutting sections. 
In order to do immunohistochemistry, 4 μm thick slices are required. 
These are cut with a microtome. The microtome uses special single-use 
razors that can move in one direction, while the paraffin block is fixed on 
the machine. The sections are gently picked up and placed in a water 
bath, at 45 degrees Celsius, so that wrinkles are removed. The best 
sections are placed on microscopic slides. 
Before staining, the sections need to have the paraffin removed and to be 
rehydrated. The opposite procedure of dehydration is followed: Starting 
with xylene, the sections are placed in several ethanol solutions with 
decreasing concentrations until they reach distilled water. This time, 5 
minutes per solution suffice. At this point the tissue samples are ready for 
staining. 
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3.3.2 Haematoxylin – Eosin Staining 
Haematoxylin – Eosin Staining (HE) is a standard histological staining that 
stains cell nuclei blue and cytoplasm and other structures in shades of red 
and pink. Haematoxylin (it means “blood-wood”) is a substance that 
comes from the core of logwood trees. When oxidized, it can bind with 
aluminium or iron ions. The solution of oxidized haematoxylin and 
aluminium ions is called hemalum and is the first substance that is 
applied on the sections on the microscopic slides. Haematoxylin is a basic 
dye and therefore it stains acidic parts of the cell such as the nucleic acids 
(DNA and RNA) and is therefore responsible for the blue staining of the 
nuclei.  
The sections are then counterstained with eosin Y. Eosin is a fluorescent 
acidic dye and it stains structures of the cell containing basic proteins, 
such as cytoplasm, pink-orange. Red-blood cells are also stained red. 
Structures that can be stained with eosin are termed eosinophilic. There 
are two kinds of eosin, eosin Y (staining red-pink) and eosin B (staining 
blue). 
After staining, the slides are shortly dehydrated and then they are 
covered with cover glasses. They can be viewed under a light microscope. 
Fluorescent microscopy can also be used to view eosin stained structures. 
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3.3.3 Trichrome Staining 
The term “Trichrome” (it means “three-coloured”) is used to describe a 
series of staining-combinations that apply 3 different stains. The one 
routinely used in TEB is the Gomori Trichrome Stain. It stains cell nuclei in 
dark-blue, cytoplasm and muscle cells red and connective tissue green or 
blue.  
The staining is performed in 3 steps. In the first step Bouin’s  picro-formol  
is applied on the sections. This is a solution that contains picric acid 
(2,4,6-trinitro-phenol), a very acidic yellow coloured substance that has 
been mostly used as an explosive. The second step involves dark blue 
staining of the sections’ nuclei with iron haematoxylin (in contrast to the 
aluminium haematoxylin used in HE staining). The last step consists of the 
application of the trichrome solution which contains a red dye called 
Chromotrope 2R and a green dye called Fast Green FCF. 
The procedure is completed with two one-minute dehydration steps and 
the use of protective cover glasses on the microscope slides.  
 
3.3.4 Immunohistochemistry 
Immunohistochemistry is the technique where antibodies are used to 
bind on specific antigens of the tissue and stain them with a dye, 
fluorescent or otherwise. It can stain the tissue in one step, by selecting 
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antibodies that bind on a specific location and which carry a reporter 
molecule (molecules that can easily be detected under a microscope) 
(direct method) or it can be done in two steps, with a primary and 
secondary antibody; the primary antibody will bind on the specific 
location and the secondary will only bind on the primary antibody and 
will carry the reporter molecule (indirect method). The indirect method is 
somewhat more time consuming but delivers better results due to the 
use of more protein-specific antibodies. 
The procedure starts with the blocking of non-specific sites on the tissue, 
i.e. sites that resemble the target sites and would otherwise be weakly 
stained and create a background staining. This is done with a solution of 
normal serum in Triton-PBS. Triton is a detergent that helps to reduce the 
surface tension of the sections and allow the antibodies cover the tissue 
samples easier.  
The next step is the application of the primary antibody. After a short 
incubation time, the microscopic slides are washed with PBS. Then the 
sections are stained with a secondary antibody, labelled with a 
fluorescent reporter molecule (FITC of TRITC, fluorescein isothiocyanate 
or tetramethylrhodamine isothiocyanate respectively). If the primary 
antibodies are from different species, the sections can be double stained 
with two primary and two secondary antibodies. The secondary 
antibodies must then be selected so that they are bound to the specific 
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primary antibodies.  After the application of the secondary antibodies, 
the sections are washed again in PBS. 
Optionally, the sections can be counterstained with another antibody, 
with the direct method. This helps to improve the contrast in the 
sections. In the TEB, DAPI (4',6-diamidino-2-phenylindole) is routinely 
used. DAPI is a fluorescent stain that binds to DNA and therefore it stains 
cell nuclei. 
For the negative controls, the secondary antibody is used without the 
primary antibody, and a total lack of fluorescence is expected. 
The last step is the placement of protective cover glasses. In order to 
observe fluorescent stained sections, a fluorescent microscope is 
necessary. Pictures can be taken combining the DAPI and another FITC or 
TRITC staining, or even all three in cases of double staining. 
 
3.4 Evaluation of the Bioreactor System 
 
3.4.1 Cultivation of Blood Vessels in the Bioreactor 
Evaluation experiments were performed on tissue engineered (TE) 
vascular grafts as well as on native vessels. The procedure of the 
experiments was the following. 
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If a TE vessel is used, the cells are firstly harvested and the components 
of the vessel are mixed in the mould, as described in paragraph 3.2.3. 
Then the vessel is left to polymerise for 45 minutes at least in which time 
the bioreactor system can be assembled, as in paragraph 2.1.8. In case 
the vessel has been cultivated statically first, this is not necessary. 
The native vessel is also prepared after the bioreactor system has been 
assembled, so that it can be immediately placed in the vascular graft 
chamber with bioreactor medium. 
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Figure 3.3: Top: TE vessel in the VGC, Middle: Porcine carotid artery in the VGC,  
Bottom: Fitting of the chamber connectors to a porcine carotid artery 
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The aims of the experiments performed were: 
1) To assemble the system, change the bioreactor medium and 
let the system run over 2 weeks at least under sterile 
conditions. 
2) To mimic physiological conditions of O2, CO2, temperature 
and nutrition delivery. 
3) To create adjustable pressure, including pressure pulses 
which should have easy to modify characteristics (amplitude, 
frequency, profile).  
4) To validate the ability of accurate and repeatable 
measurements of the compliance of vascular grafts. 
 
3.4.2 Measurement of the Diameter and Estimation of Compliance 
The diameter of the vessels was measured under dynamic and static 
conditions. The dynamic measurement was performed according to ISO 
regulations [ISO 1998a], using pressure pulses between 80 and 120 
mmHg at a frequency of 1 Hz. The measurements were performed every 
hour and for 10 consecutive pulses the pressure and the corresponding 
diameter of the vessels were recorded. The compliance was calculated 
for each pulse and the mean value and the standard deviation for each 10 
pulses was determined.  
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The static measurement consisted of setting the first pressure value (80 
mmHg) and waiting for one minute for the diameter to reach a stable 
value. The value of pressure and diameter was recorded and the 
procedure was repeated for the second pressure value (120 mmHg). This 
measurement was performed once a day and for its duration, the 3 way 
cork at the beginning of the secondary circuit was turned to the closed 
position so that the effect of the outer pressure of the vessel would be 
minimal (since the VGC is connected directly to the reservoir). 
 
3.4.3 Testing of Vascular Grafts 
The compliance of 21 vascular grafts was measured within collaboration 
with the Medical School of Hannover (PD Dr Matthias Wilhelmi and Dr 
Ulrike Böer, GMP-Muster-Labor Tissue Engineering, MHH Hannover, 
Germany). The grafts included 3 Gore-Tex prostheses, 6 equine carotid 
arteries, 6 decellularised equine carotid arteries and 6 decellularised 
equine carotid arteries after implantation in a sheep model, as listed in 
table 3.1 [Filbry et al. 2011]. 
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Sample Number Sample Description Sample Length (cm) 
1 Gore-Tex 7,2 
2 Gore-Tex 7,1 
3 Gore-Tex 7,1 
4 Native vessel 4,6 
5 Native vessel 4,6 
6 Native vessel 4,6 
7 Native vessel 4,6 
8 Native vessel 4,6 
9 Native vessel 4,6 
10 Decellularised vessel 4,6 
11 Decellularised vessel 4,6 
12 Decellularised vessel 4,6 
13 Decellularised vessel 4,6 
14 Decellularised vessel 4,6 
15 Decellularised vessel 4,6 
16 Explanted vessel 3,5 
17 Explanted vessel 4,0 
18 Explanted vessel 3,5 
19 Explanted vessel 4,7 
20 Explanted vessel 3,0 
21 Explanted vessel 4,7 
   
Table 3.1: List of Vascular Grafts that were tested in TEB 
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The compliance of all vessels was measured dynamically under two 
pressure differences: between 80 and 120 mmHg and between 40 and 60 
mmHg (figure 3.4). Some of the vessels could not be tested. More 
specifically in vessels 5, 7 and 8 it was not possible to stop the leakage 
through branching vessel openings while vessels 18 and 20 were too 
short to perform a measurement. 
Suture retention strength tests were performed on a Zwicki-Line Z2.5 
(Zwick GmbH&Co, Germany) tensile strength testing machine with an 
Ethicon Plus 2-0 suture with a taper point needle. The samples were 
pierced by the needle approximately half a centimeter from the edge and 
on the other end they were fixed on a metal connector. Then they were 
pulled with a force controlled speed of 0,2 N/min and a preloading of 
0,18 MPa, until the vessels were torn by the suture (figure 3.5).  
Burst strength tests were performed on a 15x15 mm piece of each 
sample. The parts of the vascular grafts close to the edges of the grafts 
were avoided because they had already been under stress during the 
suture retention strength tests and the compliance measurements. 
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Figure 3.4: Equine carotid artery mounted in the Vascular Graft Chamber 
   
Figure 3.5: (Left) A vascular graft placed in the tensile strength machine,  
(Right) A vascular graft under stress
4. Results 
 
4.1  Assembly of the Bioreactor System and Cultivation of 
Vascular Grafts 
 
The bioreactor system was assembled under sterile conditions in the way 
described in paragraph 2.1.8. The medium could be changed without 
opening the system and vessels were cultivated for up to 4 weeks 
without contamination. 
In figure 4.1 the results from HE and trichrome staining are presented for 
3 samples. The first one is a porcine carotid artery (PCA) that was fixed 
immediately after its preparation, without being mounted in a bioreactor 
system of being cultivated. The second sample is a porcine carotid artery 
that was placed in a bioreactor and was cultivated for 2 weeks under 
pulsatile flow of 70 ml/min in average. The pressure pulses had amplitude 
of 40 mmHg, between 80 and 120 mmHg and the pulse frequency was 1 
Hz. The third sample was conditioned under the same conditions like the 
second but with higher frequency (2 Hz).  
Figure 4.2 contains the results from immunohistochemical staining of the 
same samples for collagen type I, collagen type III, elastin and smooth 
muscle actin (SMA). The first three antibodies share the same secondary 
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antibody and therefore they have the same negative control while for 
SMA a different secondary antibody is used. The samples were 
counterstained with DAPI. 
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Figure 4.1: Haematoxylin – Eosin and Gomori Trichrome staining pictures of a 
porcine carotid artery, a porcine carotid artery cultivated under 1 Hz pressure 
pulses and a porcine carotid artery cultivated under 2 Hz pressure pulses. Scale 
bars are 200 μm. All vessels were cultivated in the bioreactor for a period of 2 
weeks. 
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Figure 4.2: Immunohistochemistry staining for Collagen type I, Collagen type III, 
Elastin and Smooth Muscle Actin of a porcine carotid artery, a porcine carotid 
artery cultivated under 1 Hz pressure pulses and a porcine carotid artery 
cultivated under 2 Hz pulses. All vessels were cultivated in a bioreactor for a 
period of 2 weeks. Scale bars are 200 μm. 
 
4.2  Monitoring of Blood Gases 
 
In figure 4.3, the pO2, pCO2, pH and temperature values are presented, as 
they were measured in the arrangement with the blood gas sensors 
chamber attached to the system. The data is based on 569 values, 
measured over a period of 6 days, on an experiment with TE vessels. 
Figure 4.4 shows the same data, except the temperature, on a system 
without blood gases monitoring, where the properties of the medium 
were measured with a blood gas analyser (ABL800 Flex, Radiometer 
GmbH, Willich, Germany) from day 3 to day 15 (5 values) of an 
experiment with porcine carotid arteries. The temperature of the second 
system was monitored through the incubator display and was maintained 
at 37 degrees throughout the experiment. 
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Figure 4.3: The diagrams of pO2 and pCO2 (top), pH (middle)  
and temperature (bottom) in a continuous monitored system. 
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Figure 4.4: Top: pCO2 and pO2 values, Bottom: pH value of a system  
without continuous blood gases monitoring 
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4.3 Pressure Pulse Profiles Creation 
 
The pulses were generated as described in paragraph 2.2.6 and they were 
modified according to the frequency, so that the resulting pressure pulse 
on the vessel is close to the physiological form. The values that were used 
can be found in table 4.1. Figure 4.5 shows the resulting form of the 
created pulses that were translated in voltage and were applied to the 
actuator through the amplifier (top part of each picture) and the actual 
pressure pulses as they were measured through the pressure sensors 
(average of the two values before and after the vascular graft) (bottom 
part of each picture). There pulses were applied on porcine carotid 
arteries for a period of two weeks. 
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  Parameter a Parameter b Parameter c 
1 Hz 
Function 1 40 2 0,07 
Function 2 7 1,7 0,2 
Function 3 6 2,4 0,005 
Function 4 10 3,6 0,5 
2 Hz 
Function 1 40 2 0,07 
Function 2 5 1,7 0,2 
Function 3 4 2,4 0,005 
Function 4 6 3,6 1,5 
5 Hz 
Function 1 42 1,5 0,5 
Function 2 2 1,7 0,2 
Function 3 0 2,4 0,005 
Function 4 0 3,6 1 
     
Table 4.1: Parameters of the Pulse Pressure Profiles at 1, 2 and 5 Hz 
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Figure 4.5: Voltage Pulses created in the computer and corresponding pressure 
pulses, measured in the VGC. (A) 1 Hz, (B) 2 Hz, (C) 5 Hz. 
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4.4 Compliance Measurement and Mechanical Testing 
 
4.4.1 Static and Dynamic Measurement of the Compliance 
Figure 4.6 shows the compliance of a porcine carotid artery measured 
dynamically over a period of 38 hours with the pulse profile depicted in 
figure 4.5A. The error bars represent the standard deviation of each 10-
pulse measurement. The mean value (mean of means) of circumferential 
compliance (CC) is:  
CCdyn = 0,0275 %/mmHg 
The standard deviation of all measurements (of all 380 pulses) is: 
SDdyn = 0,0029 %/mmHg 
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Figure 4.6: Dynamic measurement of the circumferential compliance of a porcine 
carotid artery over 38 hours. The error bars represent the standard deviation of 
each measurement, based on 10 pulses. 
 
Figure 4.7 presents the compliance of the same vessel measured 
statically over a period of 5 days. The error bars represent the 
measurement reading error due to the accuracy of the instruments with 
reading errors of 1 mmHg for pressure and 0,01 mm for diameter (see 
Appendix 7.3). The mean value and the standard deviation over the 
complete series are: 
CCstat = 0,0327 %/mmHg 
SDstat = 0,0030 %/mmHg 
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
0 10 20 30 40
C
ir
cu
m
fe
re
n
ti
a
l C
o
m
p
li
a
n
ce
 
(%
/m
m
H
g
)
time (hours)
4 | Results 
 
 
113 
 
 
 
Figure 4.7: Static measurement of the circumferential compliance of a porcine 
carotid artery over 5 days. The error bars represent the measurement accuracy 
through the reading error of the instrumentation 
 
4.4.2 Mechanical Testing of Equine Carotid Arteries 
 
The results of the compliance measurement of the 16 vessels that were 
measured (according to paragraph 3.4.2) are presented in the following 
figure. 
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Figure 4.8: The values of Circumferential Compliance of the 4 kinds of vessels 
under 2 different pressure differences. The error bars represent the standard 
deviation (n=3 for Gore-Tex and Native and n=4 for Decellularised and 
Explanted). Statistical significance is noted in the cases where p<0,05. 
 
Figure 4.9 presents the results of suture retention strength testing. The 
top diagram shows the maximum force that the vessels withstood and 
the bottom diagram shows the maximum elongation when they were 
torn. 
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The native, decellularised and explanted vessels all withstood a pressure 
of 4000 mmHg without bursting while the Gore-Tex vessels had a burst 
pressure of: 
BPGore-Tex = 514 ± 73 mmHg (mean ± standard deviation, n=3). 
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Figure 4.9: Suture retention strength results. Top: maximum Force, bottom: 
maximum elongation. Data points represent mean ± standard deviation (n=3 for 
Gore-Tex and Explanted, n=5 for Native and Decellularised). Statistical 
significance is noted in the cases where p<0,05. 
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5. Discussion 
 
5.1 Pressure Pulse Profile Creation 
 
By changing the parameters of the equation 2.5, we can generate 
virtually any wave form that may be necessary, if enough functions are 
added. In the program that has been developed 4 functions are added 
which are adequate for the purposes of this bioreactor system. Changing 
the pulse frequency leads to a different response from the tissue, 
depending on its mechanical properties. Different cases were examined 
in an attempt to examine the versatility of the system in the generation a 
pulse that will result to a physiological pressure waveform. 
Figure 4.3 shows 3 of those pulses that were used on different blood 
vessels (native carotid arteries) under different pulse frequencies. It can 
be seen that in the cases of 1 and 2 Hz the resulting pressure pulse 
resembles the physiological standard while in the case of 5 Hz this was 
not possible. All attempts to create the secondary pressure peak resulted 
in lower amplitude pressure pulses on the vessel. It seems that the vessel 
needs some time between two consecutive pulses in order to return to 
its low pressure state and by adding the second peak we effectively 
eliminated this time space so the next pulse started before the vessel had 
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completely relaxed so the procedure resulted to lower pressure 
amplitude. This is the reason why the parameter a (the one responsible 
for the amplitude, equation 2.5) in 3 out of the 4 equations in table 4.1 is 
very low or even 0. Parameter b, controlling the centre of the curve is 
low, in order to start the pulse at the very beginning of each time frame 
and give the vessel time to return to its low pressure state before the 
next pulse. In this way it is made possible to create a 5 Hz pulse 
frequency with relatively low current and subsequently lower force. 
The creation of higher frequency pulses is also possible, but studies 
should be carried out in advance in order to research the appropriate 
amplitude, since high forces are potentially harmful to the cells and a 10 
Hz pulse, for example, between 80 and 120 mmHg would create quite 
high accelerations and therefore forces applied on the cells. 
The pressure pulses generated comprise a definite improvement over 
previous systems. Shaikh et al. generated simple sinusoidal pulses of 0,5 
Hz using an air pump [Shaikh et al. 2010] while Narita et al. changed the 
compliance of the entire system in order to adjust the form of the pulses, 
being able to generate a wide range of profiles, but without controlled 
and accurately adjustable parameters [Narita et al. 2004]. Finally, the 
system that was developed by Thompson et al. used a ventilator to 
produce an approximation of physiological pulses which did not succeed 
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in creating the second peak observed in physiological brachial or aortic 
pressure waveforms [Thompson et al. 2002].  
The system is therefore able to create adjustable pressure pulses, as 
close to physiological form as the frequency allows, that can be tailored 
for each type of tissue. It may be interesting to conduct experiments 
evaluating the effect of the form and the amplitude of the pressure 
profiles to the creation of ECM and the proliferation of cells.  
 
5.2 Monitoring of Blood Gases 
 
Two methods were presented and tested, concerning the measurement 
of blood gases, namely O2, CO2 and pH. The first one included the blood 
gas sensors chamber as an element of the bioreactor system, so that the 
values can be monitored continuously and the second one was based on 
sampling and testing the medium with an external blood gas analyser.  
Figure 4.3 presents the results of the continuous method over 6 days. The 
big advantage is that there is a close control of the values and even small 
differences can be observed and traced back to their possible cause. For 
example, in the diagram showing the partial pressures of O2 and CO2 it 
can be clearly seen that there is an abrupt change between days 1 and 2 
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and on day 3. This change is a result of the adjustment of the pressure of 
CO2 in order to bring its partial pressure in the system closer to its 
physiological value, affecting the value of the O2 and the pH as well. The 
temperature change on day 4 reveals the attempts made to decrease the 
high temperature of the system, by decreasing the incubator 
temperature. A cooling pump was later included in the system in order to 
better control the temperature that tended to exceed 37 degrees Celsius 
because of the heat produced by the circulator pump inside the 
incubator. 
On the other hand, the presence of the blood gas sensor chamber was 
the difference between accommodating the bioreactor system in one or 
two shelves of a standard incubator (figure 5.1). One shelf would allow 
two systems to run in parallel in one incubator. This can be an important 
characteristic of a system where different methods will be tested through 
long term experiments. 
Figure 4.4 shows the blood gases as they were measured with an external 
blood gas analyser. Much fewer values were used to create these graphs 
(a sample was tested approximately every second day) which explains the 
absence of abrupt changes because of CO2 regulation or long inspection 
times of the setup in the incubator. The graphs offer a good overview of 
the blood gases and they are consistent to each other (a fluctuation in 
the partial pressure of CO2 can also be noticed in the pH graph). 
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Nevertheless, small changes due to actions performed during the 
experiment have not been recorded. This method has, therefore, the 
disadvantage of a less close control of some parameters that may 
influence the environment for a short time and, of course, the obvious 
necessity of performing regular blood gas tests.  
The advantage is that two systems can fit in an incubator (figure 5.1, 
bottom) and the system is slightly easier and faster to assemble. 
Therefore it may be concluded that when closed control of the system is 
required (e.g. when new elements or methods are tested) or when a 
system needs to run for a long time and it may be inconvenient to take 
samples for measurements every day or every second day, the 
continuous measurement of blood gases should be the preferred 
solution. When a standard configuration of the bioreactor is used to 
perform similar experiments, the sampling method provides more space 
in the incubator and relatively easier assembly of the system. 
El-Kurdi et al. used a continuous monitoring system with two loops, one 
for the flow though the vascular graft and one for the outer flow [El-Kurdi 
et al. 2008]. In the main loop (through the vessel) the standard deviation 
(SD) of the pH measurement over a 24 h experiment is not provided, but 
the mean value varied within a range of 0,06 approximately (7,33 – 7,39). 
The pO2 and pCO2 measurements varied approximately in a range of 140 - 
150 and 42-48 mmHg respectively. Finally, the temperature range was 
5 | Discussion 
 
 
122 
 
roughly 36 - 38°C. The results cannot be very well compared 1 to 1 to our 
findings, since that system ran for a short time with very intense 
monitoring in order to examine specific responses from their automatic 
controller while the system presented in this study aims at the long term 
monitoring of tissue-engineering grafts. The range that the values vary, 
though, over 24 hours periods, are in the same order of magnitude, of 
±1°C for temperature, ±5 mmHg for O2 and CO2 partial pressures and 
±0,05 in the case of pH. 
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Figure 5.1: Two (top) and one incubator shelf (bottom) arrangements for  
the bioreactor system depending on the use of the blood gas chamber. 
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5.3 Assembly of the Bioreactor System and Cultivation of 
Vascular Grafts 
 
The final version of the system proved to be easy to assemble under the 
sterile workbench and easy to change bioreactor medium to. Its modular 
design allows including as many parts as one needs for each experiment. 
Several problems and difficulties such as leakage, pressure drops, wrong 
placement of elements and others were dealt with in order to develop a 
smoothly running system. The handling of TE vessels or native vessels is 
also made easy thanks to the versatile connectors that are used which 
allow the mounting of the vessel outside of the bioreactor and then they 
clasp easily with the connectors inside. 
Native porcine carotid arteries were used in order to test the system 
under real conditions, i.e. under conditions where sterility of the system 
needs to be maintained, the compliance of real vessels can be measured, 
the blood gases values vary and where the condition of living cells can be 
examined with the use of histological staining. TE vessels were also 
tested, but they introduced too many unknown variables. In order to test 
an experimental system established methods and well-studied samples 
should be used instead of vessels that are part of on-going research 
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themselves. Preclinical tests usually involve large animal experiments, 
mainly sheep and pig that have several anatomical characteristics such as 
heart valves in similar form and size like humans. Porcine carotid arteries 
were chosen due to their easy accessibility and availability. 
Examining the histology pictures one notices the difference in the DAPI 
staining between the untreated vessels (figure 4.2, first column) and the 
vessels that were conditioned in the bioreactor (figure 4.2, columns 2 and 
3). The untreated vessels have brighter and denser staining. This result is 
confirmed from the HE staining (figure 4.1, first row). In the image of the 
untreated sample the cell nuclei are more pronounced and spread 
through the section. In addition it can be observed in both figure 4.1 and 
4.2 that the treated vessels have thinner walls than the untreated 
vessels. Looking at the HE and trichrome images it seems that especially 
the tunica media, the second layer of the vessel has become thinner. In 
the untreated images, the media seems to be 3-4 times thicker than the 
tunica adventitia, the outer layer, but in the treated vessels images, the 
media is only 1-2 times thicker. The treated vessels seem to have 
undergone a partial media necrosis, i.e. a reduction of cells of the media 
and a subsequent compression of the vessel wall and especially the 
media. 
Literature on native vessels placed into bioreactor systems is scarce, but 
they sometimes come in contact with foreign materials for an extended 
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time period as in the case of stents, after operations of balloon 
angioplasty. In these cases remodelling of the vessels is common, usually 
resulting in a thickening of the intima and media layers [Dirsch et al. 
2004]. In one case porcine carotid arteries were placed in a bioreactor 
system in order to test the proliferation of smooth muscle cells under the 
effect of three types of stents. The artery was cultivated with pulsatile 
flow between 80 and 120 mmHg, with bioreactor medium (DMEM with 
10% foetal bovine serum and 1% antibiotics) for 7 days. In order to 
evaluate smooth muscle cell proliferation, immunohistochemistry was 
performed with BrdU (bromodeoxyuridine), a stain used to detect cells in 
the S-phase, when they duplicate their chromosome. The study showed 
almost zero proliferation in the part of the vessels that did not come to 
contact with the stents. In addition, it was measured that the contractile 
capacity of the vessels after 7 days in the bioreactor was 45% of native, 
untreated vessels [Yazdani & Berry 2009].  
A certain amount of remodelling and media necrosis was then to be 
expected. Native vessels are deteriorating when they are transferred 
from a “perfect bioreactor” such as a living organism to an artificial 
environment, due to the absence of signals, growth factors and the 
absence of a functional capillary network. In the bioreactor they rely on 
perfusion of nutrients from the bioreactor medium through the tissue, 
and shrinkage of tissue may be one way to facilitate this process. Native 
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vessels do not behave like TE grafts, which in a bioreactor find a more 
physiological environment than the cell culture flasks and structure 
where they can adhere to and produce ECM. 
The bioreactor environment seems on the other hand, despite the 
reduced cell population, to encourage the production of ECM. In figure 
4.2 collagen type I and III as well as elastin are much more pronounced 
than the untreated vessels. We cannot be certain if more proteins were 
produced in the first days, when cells were wider spread or if the 
surviving, stronger cell population increased protein production during 
the last days. A relative increase in the density of collagen I, III and elastin 
could be explained in account of the shrinkage of the vessel, but the 
difference in figure 4.2 seems to be significantly higher than that. It 
would be very interesting to perform experiments that would run for 3, 6, 
9 and 12 days, for example, which could investigate this effect in 
comparison with cell number and wall thickness. 
 A further point that can be made is that there is a noticeable difference 
between the vessels that were conditioned under 1 and 2 Hz pulse 
frequencies. In figure 4.2, top two rows, the staining for collagen type I is 
more pronounced for the2 Hz artery than the 1 Hz. The same happens in 
the case of collagen type III, but in a smaller degree. Overall, the DAPI 
staining is stronger in the 2 Hz vessel compared to the 1 Hz. The 
interesting question that arises is whether this difference is due to the 
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higher forces developed on the cells, because of the increased 
acceleration caused by the high frequency or to the bigger amount of 
pulses delivered to the vessel, which means that a 1 Hz pulse experiment 
will have the same result, but in a longer time. The study of Dirsch et al. 
showed a repopulation of the necrotic area of the media within 4 weeks. 
Of course, the case is not the same, but it seems that a systematic 
approach of the culture conditions could reveal the parameters that 
affect the porcine carotid arteries in vitro and a mechanical conditioning 
protocol can be developed to optimise the cultivation of native as well as 
TE vessels.  
As a conclusion we could say that the bioreactor system seems to 
promote the production of ECM matrix despite the expected reduction of 
the cell population. In addition, the different conditioning patterns result 
in different amounts of ECM production, as is well documented in 
literature [Narita et al. 2004; Gilbert et al. 2007; Lanzarone et al. 2009]. 
 
5.4 Compliance Measurement and Mechanical Testing 
 
5.4.1 Static and Dynamic Measurement of the Compliance 
The two methods that were presented for the measurement of the 
compliance, dynamic and static, resulted in two quite different 
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circumferential compliance values. More specifically, the dynamic 
method gives a 16% lower value than the static. This difference is to be 
expected, since the static measurement requires the system to reach 
equilibrium by waiting 1 to 2 minutes, in which time the vessel expands 
further. This means that under pulsatile pressure the system doesn’t have 
enough time to reach its equilibrium extremes. This was also observed 
during test runs that the compliance was measured under higher 
frequencies. The values calculated under higher frequencies were 
significantly lower. 
The standard deviations (SD) of the two measurements are very close, 
0,0029 and 0,0030 %/mmHg for the dynamic and the static method 
respectively. This result seems to imply that the two methods have 
similar accuracies, but this is misleading. First of all, if the SD is expressed 
as percentage to the mean, the values would be: 
CCstat = 0,0327 ± 9,2% (%/mmHg) and CCdyn = 0,0275 ± 10,5% (%/mmHg) 
Another point is that the dynamic measurement is based on 378 
measurements of pressure and diameter and the static measurement 
only on 5. Very small samples have unreliable SDs that may differ 
significantly from the SD of a large sample. In addition, the dynamic 
measurement was performed over 38 hours while the static over 5 days 
and compliance is not a given property that remains unchanged. A 
measurement that extends over a long period of time tends to be more 
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inaccurate and the standard deviation is increased. For this reason, the 
standard deviation is not a sensible measure for the measurement of a 
changing property over a long period of time. This can be seen very well 
in figure 4.7. The compliance of the last 3 days is slightly reduced 
compared to the first two. 
Another interesting result emerges if we compare the accuracy of 
measurement of each point in the two methods. The points in the 
dynamic measurement are the mean values of calculations based on 10 
pulses and the error bars are equal to 2 SD (figure 4.6). These are in 
average (average of all SDs) equal to 0,0027 mmHg, a value very close to 
the SD of the complete sample. On the other hand, the error bars in the 
static measurement (figure 4.7) which are single measurements are the 
reading errors due to the instruments used, i.e. the pressure sensors and 
the optical micrometre. The errors of these two instruments were 
estimated at 1 mmHg and 0,01 mm respectively and the error for the 
compliance is, on average, equal to 0,0074 %/mmHg. This figure is not 
completely representative of the accuracy with which the true value of 
the compliance is known, because the vessel is flexible and is placed into 
a chamber filled with circulating fluid. Our method consists of estimating 
the true compliance based on diameter measurements and therefore it is 
prone to some error because of random movements of the vessel. 
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Nevertheless, it is indicative of the sensitivity of the organs and the 
accuracy of each single measurement. 
This problematic, of calculating the SD of compliance for the same vessel 
over a long period of time does not occur in literature, because most 
studies compare vessels which underwent different treatments and the 
compliance is often measured once per vessel. Nevertheless all 
compliance measurements have a SD in the range of 10 to 20%, 
regardless of the measurement method used. Syedain et al. cultivated 
groups of 6 TE grafts in parallel and compared 2 mm and 4 mm in 
diameter grafts to native ovine femoral arteries. The SDs of the 
compliance values varied between 20 and 40% of the mean [Syedain et 
al. 2011]. The compliance was measured with an optical micrometre, 
dynamically and only once, before the vessels were pressurised until the 
point of bursting. Another study measured the compliance of TE vessels 
based on cell sheets and the SD for a group of 3 vessels, were 20% of the 
mean value [L'Heureux et al. 2006]. 15-20% of the mean compliance 
(termed “distensibility” in that study) was also the SD of the ultrasound 
measurements of human mammary and radial arteries, according to 
Chamiot-Clerc et al. [Chamiot-Clerc et al. 1998]. Vismara et al. measured 
the compliance of decellularised heart valve grafts dynamically, with 
pulses created by a peristaltic pump, and a SD of the mean value of the 
compliance of 11-16% [Vismara et al. 2010]. It can be argued that 
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measurements performed on blood vessels from different species are not 
very well comparable due to the difference in diameter and the 
respective volume. Compliance is very sensitive to diameter changes and 
relatively small changes can lead to significant compliance variation. 
However, our results are within the accuracy range that is found in 
literature. 
 
5.4.2 Mechanical Testing of Equine Carotid Arteries 
 
This study of the mechanical properties of the 21 vessels is an excellent 
example for the demonstration of compliance as a good index of 
mechanical behaviour. If one would first look at the results of suture 
retention testing (figure 4.9), it would become apparent that the native 
vessels and the decellularised vessels are stronger and more elastic 
compared to the other two kinds, the Gore-Tex and the explanted ones. 
The burst strength results verify that the Gore-Tex is the weakest of the 
group and that the native vessels can easily withstand pressures within 
physiological limits. These tests are all destructive ones. The vessels have 
to be removed from the bioreactor or explanted from the animal, and 
they have to be damaged through the testing process.  
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Compliance measurement can be performed in the bioreactor system, as 
it was performed in this case, or in the organism with the use of one of 
the techniques discussed in the introduction, such as ultrasound or MRI. 
And the results (figure 4.8) are in accordance with the suture retention 
testing results. The native and the decellularised vessels proved to be the 
most compliant under both pressures.  
The Gore-Tex vessels have the poorest mechanical properties, 
compliance and burst strength. The decellularised vessels are very similar 
to the native ones, with differences that are not statistically significant. It 
seems, therefore, that the decellularisation process alone does not affect 
the vessels critically. It is very interesting to see, however, what happens 
after the implantation in a sheep model. The mechanical properties 
decrease significantly, to such an extent that there is no statistically 
significant difference between the decellularised and the Gore-Tex grafts. 
Apparently the process of reseeding instead of reinforcing the ECM leads 
to its remodelling and protein denaturation, lowering its elasticity and 
the suture retention strength. 
Another interesting point is the relation between the value of compliance 
measured at low pressure (40 – 60 mmHg) and the one measured at high 
pressure (80 – 120 mmHg). Lower pressure resulted to higher compliance 
values in almost all cases. This is due to the fact that the vessels have a 
much bigger capacity to expand when they are relatively relaxed, i.e. at a 
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low pressure. As pressure is increased, the vessels stretch more and a 
given pressure difference will amount to a smaller diameter difference. In 
this case, the lower pressure was accompanied by lower pressure 
difference as well (20 mmHg against 40 mmHg), but even so the 
compliance value was higher. 
 
5.5 Conclusions 
 
A bioreactor system has been developed for the cultivation, mechanical 
conditioning and mechanical testing of vascular grafts. The system is 
designed on a modular principle which allows us to include or exclude 
different elements. In addition, it allows the continuous measurement of 
blood gases and the measurement of the compliance in vitro. 
Furthermore, the system has the ability to create adjustable pressure 
pulse profiles and therefore allows the establishment of conditioning 
protocols tailored to the needs of each experiment. It can also be used 
for the performance of accelerated durability tests on tissue engineered 
or otherwise vascular grafts according to the standards of the 
International Organisation for Standardisation. Thus, this study 
introduces a system with novel elements that can assist the science of 
vascular tissue engineering towards its clinical implementation. 
6. Summary 
 
Cardiovascular disease is the leading cause of death worldwide despite 
the progress that has been made in established surgical treatments such 
as the coronary artery bypass surgery and the balloon angioplasty. Tissue 
engineering (TE) has already offered clinical solutions in the areas of skin 
and cartilage regeneration and is advancing in several research fields, 
such as vascular graft replacements. In order for TE constructs to be 
cultivated and conditioned under a controlled environment, bioreactors 
systems are used, that can maintain physiological O2 and CO2 
concentrations and can apply stresses and strains to promote the 
proliferation of cells and the production of extracellular matrix proteins. 
In the case of cardiovascular TE, conditioning under pulsatile pressure is 
common practice by many groups. 
In this study a bioreactor system is presented that can apply adjustable 
pressure pulse profiles to vascular grafts under a controlled environment. 
In addition, it can perform diameter measurement of the vessels in vitro 
so that the compliance of the vessel can be calculated. The compliance, 
which is the relative change of volume of a vessel due to a pressure 
change, is an excellent measure of its mechanical condition and can be 
used to monitor the development and maturation of the newly formed 
tissue. 
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The system uses a centrifugal pump that pumps cell culture medium from 
a reservoir and supplies a perfusion bioreactor. Medium flows both 
through and around the vessel and its blood gas values, namely the 
partial pressures of O2 and CO2 and its pH value are monitored with the 
respective sensors in another chamber. A linear motor with a piston 
controlled by a computer applies pulses through a silicone membrane. An 
application developed in Labview® is used to generate the pulses, record 
the pressure, the flow and the blood gas values and the diameter of the 
vessel through an optical micrometre. 
The system was evaluated with experiments that lasted up to 4 weeks, 
where TE vessels and native porcine carotid arteries were cultivated and 
conditioned. The results demonstrated that it can be easily assembled 
under sterile conditions and run without problems for this time. The 
blood gases were monitored either with the blood gas chamber or 
externally, with a blood gas analyser and the compliance could be 
measured accurately over the cultivation period. The system can also be 
used for the performance of durability testing according to existing 
regulations for similar products (heart valves and stents), issued by ISO 
and FDA, and assist in the procedure for clinical approval of tissue 
engineered vascular grafts. 
7. Appendix 
 
7.1 Protocols 
 
7.1.1 Bioreactor Medium 
 
• Dulbecco’s Modified Eagle’s Medium (DMEM) 500 ml 
• Ascorbic Acid (MW 289,54)   0,1607 g 
• Foetal Calf Serum    50 ml 
• Antibiotic – Antimycotic solution  5 ml 
 
7.1.2 Phosphate Buffered Saline (PBS) 
 
• Potassium Chloride (KCl)   0,2 g/l 
• Monopotassium phosphate (KH2PO4)  0,2 g/l 
• Sodium Chloride (NaCl)    8 g/l 
• Disodium Phosphate (Na2HPO4)  1,15 g/l 
Use distilled water. 
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7.1.3 Tris Buffered Saline (TBS) 
 
• Tris Hydrochloride (Sigma Inc.)   4,36 g/l 
• Tris Base (Sigma Inc.)    0,64 g/l 
• Sodium Chloride (NaCl)    8 g/l 
• Potassium Chloride (KCl)   0,2 g/l 
Use distilled water. PH is adjusted to 7,4 by adding a small quantity of 
HCl or NaOH. 
 
7.1.4 Transport Buffer 
 
Transport Buffer 10x 
• Sodium Chloride (NaCl)    80 g/l 
• Potassium Chloride (KCl)   3 g/l 
• Hepes       23,8 g/l 
Use distilled water. PH is adjusted to 7,5 by adding a small quantity of 
HCl or NaOH. 
 
 Transport Buffer 1x (500 ml) 
• Transport Buffer 10x    50 ml 
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• Antibiotic – antimycotic solution  5 ml 
• Distilled water     fill up to 500 ml 
 
7.1.5 Carnoy’s Solution 
 
• Absolute Ethanol (C2H5OH)   60 % vol. 
• Chloroform (CHCl3)    30 % vol. 
• Acetic Acid (CH3COOH)    10 % vol. 
1-2 mm thick tissue samples should be fixed for 1 hour.  
3-5 mm thick tissue samples should be fixed for 3 to 5 hours. 
After fixation, the tissue should be washed with absolute ethanol 
until there is no acetic acid odour. 
 
7.1.6 Haematoxylin – Eosin Staining 
 
1) Deparaffinising of Samples 
3 x 5 min  Xylol 
2 x 5 min 100 % vol. ethanol 
1 x 5 min 96 % vol. ethanol 
1 x 5 min  80 % vol. ethanol 
1 x 5 min 70 % vol. ethanol 
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1 x 5 min distilled water 
 
2) Mayers Hemalum (Merck 1,09249,0500) 
a. 5 seconds incubation time 
b. 10 minutes under flowing water 
 
3) Eosin Y (Sigma HAT 110-2-16) 
a. 1000 μl Eosin + 5 μl Acetic Acid 
b. 5 seconds incubation time 
c. 10 minutes under flowing water 
 
4) Dehydration with immerse in 96 % vol. Ethanol, 100 % vol. 
ethanol and xylol for 1 minute each, consecutively. 
5) Allow xylol to evaporate (5 minutes) 
6) Apply Euparal (Roth 7356.1) and cover with cover glasses. 
 
7.1.7 Gomori Trichrome Staining 
 
1) Deparaffinising of samples 
same procedure like in HE staining, paragraph 7.1.7, step 1 
2) Apply Bouin’s Solution on the samples and incubate in room 
temperature overnight or in 56°C for 1 hour. 
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3) 1 hour under flowing water 
4) Apply iron-haematoxylin and incubate for 10 seconds. 
5) 10 minutes under flowing water 
6) Apply trichrome solution and incubate for 5 minutes 
7) Wash in 0,5 % vol. solution of acetic acid in distilled water for 10 
seconds. 
8) Dehydration 
same procedure like in HE staining, paragraph 7.1.7, steps 4 and 5 
9) Apply Eurapal (Roth 7356.1) and cover with cover glasses. 
Trichrome solution:  
a) Solve 0,6 g Chromotrop 2R in 100ml distilled water  
b) add 0,3 g Fast Green FCF (or Aniline blue)  
c) solve 0,7 g phosphotungstic acid in the mixture (H3PW12O40) 
d) add 1 ml acetic acid 
 
7.1.8 Immunehistochemical Staining 
 
1) Deparaffinising of samples 
same procedure like in HE staining, paragraph 7.1.7, step 1 
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2) Block non-specific sites with normal goat serum (NGS) (apply 120 
μl / slide) 
- 5 % vol. NGS (X0907, Dako) in Triton PBS 
3) Incubation of primary antibody (apply 120 μl / slide), for 60 
minutes in room temperature (RT) or overnight at 4°C 
- Elastin: Fitzgerald 20R – ER003, 1:200 
- SMA: Sigma A 2547, 1:500 
- Collagen type I: Acris R1038, 1:200 
- Collagen type III: Acris R1040, 1:200 
4) Wash with triton PBS 3 times 
5) Incubation of secondary antibody (apply 120 μl / slide), 60 
minutes in RT 
- Collagen type I, collage type III and elastin: Alexa Fluor 488 
(Nr.A.11008) 
- SMA: Alexa Fluor 594 (Nr.A.11005) 
6) Wash with triton PBS 3 times 
7) Counterstaining with DAPI (apply 120 μl / slide), incubate for 5 
minutes in RT 
- solve 7,5 μl 300nm DAPI stock solution in 5 ml PBS 
8) Wash with triton PBS 3 times 
9) Cover with cover glasses and fluorescent mounting medium. 
Triton PBS: 0,1 % vol. of Triton X 100 in PBS  
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7.2 Bioreactor Part Drawings 
 
7.2.1 Burst Strength Chamber 
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7.2.2 Vascular Graft Chamber Frame 
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7.2.3 Vascular Graft Chamber and Connector 
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7.2.4 Medium Reservoir 
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7.2.5 Pulse Chamber 
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7.2.6 Pulse Chamber Frame 
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7.2.7 Blood Gas Sensors Chamber and Frame 
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7.3 Error Analysis 
 
When a quantity Y is a function of other measurable quantities X1, X2, X3 
etc (Y=f(X1, X2, X3, …) with errors ΔX1, ΔX2, ΔX3 etc, then the error ΔY is the 
square root of the sum of the squares of the partial derivatives of all 
variables: 
 
EΔYG# = UV>EX!, X#, X$, … GVX! ∙ ΔX!Y
# + UV>EX!, X#, X$, … GVX# ∙ ΔX#Y
#
+ UV>EX!, X#, X$, … GVX$ ∙ ΔX$Y
# +	… 
 
Circumferential Compliance is a function of 4 variables: P1, P2, D1 
and D2: 
 
 = Z# −Z!Z#&# − &! ∙ 100 
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 Therefore, the error ΔC will be calculated by the following 
equation: 
 
EΔCG# = ] ∂C∂D! ∙ ΔD!`# + ] ∂C∂D# ∙ ΔD#`# + ]∂C∂P! ∙ ΔP!`#
+ ]∂C∂P# ∙ ΔP#`# ⇒ 
 
EΔCG# = ]−D# ∙ 100&# − &! ∙ D!# ∙ ΔD!`# + ] 100D! ∙ E&# − &!G ∙ ΔD#`#
+ cZ# − Z!Z# ∙ 100E&# − &!G# ∙ ΔP!d
#
+ c−Z# − Z!Z# ∙ 100E&# − &!G# ∙ ΔP#d
#
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